Body · Sources

Menopause and the years around it

Also called perimenopause · hot flashes · night sweats · HRT · hormone therapy · menopause transition · vasomotor · midlife bone · menopause sleep · the change

Named sources. May contain inaccuracies or be incomplete. Not medical, legal, financial, or other professional advice.

Menopause names the end of menstrual periods; perimenopause is the surrounding transition. Changing cycles, hot flashes, broken sleep and bone-health questions can overlap, but they need different answers. The calendar helps describe the stage, symptom interference helps guide treatment, and age and history help guide bone assessment. Hormone therapy and several nonhormone treatments can relieve bothersome hot flashes. A useful next step is to bring your pattern and your main concern to a qualified clinician.

What changes around the last period

The stage name describes ovarian aging. It does not tell you how much help you need or when symptoms will end.

Understand menopause as a life stage with a changing hormone pattern

Menopause is the point at which periods have permanently ended because the ovaries have lost their usual follicular function. A follicle is the small structure in an ovary that contains a developing egg. During perimenopause, the years around that point, ovarian activity becomes less predictable; estrogen can fluctuate before settling at a lower level. This helps explain why changing cycles, sudden heat and disrupted nights can occur together. WHO describes substantial variation: some women have few symptoms, while others have symptoms that interfere with daily life. A normal life stage can still deserve treatment. Its significance is how it affects you, rather than whether you match someone else's symptom list. Mayo Clinic gives a U.S. average menopause age of 51, while estimates differ slightly across sources; an average age is not a personal deadline.

Menopause Menopause — Endocrine Library Menopause — Symptoms and causes

Use the calendar to describe the stage, with room for exceptions

For natural menopause, the usual marker is twelve consecutive months without a period when another cause does not explain the absence. It is retrospective: you recognize the final menstrual period after time has passed. Siobán Harlow and the STRAW+10 workshop use persistent differences of at least seven days between consecutive cycle lengths to mark early transition, and a gap of at least sixty days to mark late transition. That late stage commonly lasts one to three years; their definition of perimenopause extends through the first twelve months after the final period. The workshop intended a common framework across age, ethnicity, body size and lifestyle, while recognizing situations where bleeding criteria are harder to use. These are staging clues, not instructions to diagnose yourself. Hormonal contraception can mask bleeding. A hysterectomy removes the uterus, so the period calendar is lost even if the ovaries remain; removal of both ovaries is a different event. A clinician interprets symptoms, surgery and medication history together.

Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging Definition and Stages

Let a clinical history answer the routine midlife testing question

FSH, or follicle-stimulating hormone, is a signal involved in ovarian function. Its level can fluctuate during the transition, making one measurement a poor summary of the preceding months. NICE recommends identifying typical perimenopause or menopause clinically in otherwise healthy people aged 45 or over with relevant symptoms, rather than routinely ordering hormone or ovarian-reserve tests. That recommendation does not mean every test is useless or every new symptom is menopause. Younger age, an unusual presentation or medication-masked cycles can change the assessment. The practical preparation is a history of bleeding, symptoms and medicines. Ask what question a proposed blood test would answer before treating its number as the final verdict.

Menopause: identification and management — Recommendations (NG23)Menopause — Endocrine Library

Seek assessment when periods stop before 45

Periods stopping unusually early need assessment rather than a wait for the ordinary twelve-month anniversary. The international ovarian-insufficiency guideline distinguishes premature ovarian insufficiency, or POI, before age 40 from early menopause at ages 40–44. POI means loss of normal ovarian activity, but nonsurgical POI can include intermittent activity and a chance of natural conception. It is not synonymous with an absolute infertility verdict. The care discussion includes causes, symptoms, bone and cardiovascular health, and fertility goals. Hormone treatment may address health needs until the usual menopause age even without troublesome heat, subject to the person's history. That differs from starting hormones much later for disease prevention. The guideline also acknowledges limited evidence for many POI-specific choices; an individualized assessment remains essential.

Evidence-based guideline: Premature Ovarian Insufficiency Definition and Stages

Which part is disrupting your life?

These four situations help identify the question to bring to care. Several can be true at once.

Describe changing periods before trying to name the final one

You might be thinking, 'My periods are farther apart, but they still come—am I in menopause?' The answer is that changing cycles can fit perimenopause before menopause can be confirmed retrospectively. The Canadian Menopause Society describes the distinction through both bleeding patterns and symptoms, while NICE emphasizes the clinical story in typical midlife presentations. Write down when bleeding occurred, how it changed and whether you use hormonal medicines. Include surgery history if it applies. A symptom diary is a communication aid, not an obligation to collect a perfect year of data before asking for help. Very heavy, unusually frequent or new postmenopausal bleeding belongs in an assessment rather than being assumed to be another stage marker.

Imagine someone brings a note saying 'probably menopause' but no description of what changed. A more useful account separates changing cycle dates, interrupted sleep and how symptoms affect daily life, alongside relevant medicines or surgery. Those details give the clinician questions to assess instead of a label to accept. A missing date can be marked uncertain; it need not delay seeking help.

If a symptom improves while another persists, that is worth describing separately at follow-up. It does not mean the whole experience must have one cause or one treatment. This invented visit preparation illustrates the difference between describing a stage and investigating a symptom. It does not determine menopause from a diary, prescribe a test, or make unexpected bleeding something to watch indefinitely rather than bring to clinical attention.

Definition and Stages Menopause: identification and management — Recommendations (NG23)Heavy periods

Describe what heat interrupts, as well as how often it happens

You might be thinking, 'The heat is still interrupting meetings years later—shouldn't it be over?' A vasomotor symptom is a hot flash or night sweat: a sudden heat episode, often with flushing and sweating. The Menopause Society explains that episodes differ greatly in frequency and severity. For a visit, 'I lose my train of thought twice during most meetings' or 'I change bedding at night' can be as useful as a rough episode count. Those details describe interference, which is a meaningful treatment outcome. They help distinguish a tolerable symptom from a symptom worth treating. A new or unusual pattern of sweating still deserves clinical consideration; the word menopause should not explain away every possible cause.

Hot Flashes Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition

Describe the whole night when sleep remains difficult

You might be thinking, 'I have time to sleep, but I keep waking and cannot get back to sleep.' Night sweats can be one cause of waking, while an insomnia pattern can persist alongside them. Hadine Joffe studies these overlapping problems, and Susan McCurry's trial tested structured insomnia care in women who also had hot flashes. Tell the clinician whether heat woke you, whether you were already awake, how long returning to sleep took and what happens during the day. Also mention loud snoring, gasping or witnessed breathing pauses. The National Heart, Lung, and Blood Institute identifies these as reasons to consider sleep apnea, which requires its own assessment. A wearable's reassuring sleep score does not replace that history.

Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial Hadine Joffe — official professional profile Sleep Apnea — Symptoms

Ask about bone health and strength even without pain

You might be thinking, 'I feel fine, but do I need to change my lifting or get a bone scan?' Bone loss often gives no useful day-to-day warning before a fracture. USPSTF screening guidance uses age and fracture-risk factors rather than whether someone feels strong. Wendy Kohrt's work also distinguishes changes in muscle and body composition from symptoms such as hot flashes. Mention previous fractures, falls, medicines that affect bone and the activity you currently do. A bone-density discussion and a supervised exercise discussion serve different purposes: one helps assess risk, the other helps choose suitable loading. Neither assumes that every person needs a scan immediately or should begin heavy lifting from a generic page.

Osteoporosis to Prevent Fractures: Screening Wendy M. Kohrt — official professional profile High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial

What hot-flash research actually measured

Averages are useful for expectations. They cannot supply your personal stop date.

Allow for a course measured in years

Crandall and colleagues' clinical review estimates that roughly 50%–75% of women have vasomotor symptoms during the transition. Nancy Avis and colleagues analyzed 1,449 women with frequent hot flashes or night sweats in the Study of Women's Health Across the Nation, or SWAN. Frequent meant symptoms on at least six days in the preceding two weeks. The median total duration was 7.4 years; among 881 women whose final period was observed, symptoms persisted a median of 4.5 years after it. A median is the middle of the observed distribution, not a treatment deadline. Women reporting frequent symptoms before or early in the transition tended to have longer courses, and African American women had the longest median among the groups studied. These observations correct the idea of a universal one- or two-year limit. They do not predict one person's duration or establish an inherent biological explanation for every group difference.

Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition Management of Menopausal Symptoms: A Review

Measure relief in the outcome that matters to you

A therapy can reduce episode frequency, lessen severity, improve sleep or make heat less disruptive without doing all four equally. Myra Hunter's MENOS studies illustrate the distinction. King's College London's report describes two randomized trials: one in 96 women after breast-cancer treatment, and another in 140 otherwise healthy women with troublesome menopause symptoms. Group or guided self-help cognitive behavioral therapy improved how problematic participants rated hot flashes and night sweats, with benefits sustained through 26 weeks. The method helps with interpretations and responses to episodes; it does not imply that heat is imaginary. Research on flash counts and research on coping answer different questions. When reviewing a treatment, ask which outcome improved, compared with what, and in which group.

CBT effective in treating menopause symptoms Myra S. Hunter — official professional profile

Which treatments have evidence for heat?

Treatment choice depends on your goals, medical history, preferences, availability and the particular product.

Consider hormone therapy for troublesome symptoms

Systemic hormone therapy circulates through the body, commonly using estrogen with an additional protective medicine when needed. Carolyn Crandall, Jyothi Mehta and JoAnn Manson's 2023 clinical review describes systemic estrogen as reducing vasomotor-symptom frequency by roughly 75% on average in the reviewed research. A review estimate is not a promised result for one person. The Menopause Society's 2022 statement calls hormone therapy the most effective vasomotor treatment and records benefits for bone loss and fracture. It describes a generally favorable benefit-risk balance for appropriately selected symptomatic women younger than 60 or within ten years of menopause onset, without contraindications. That supports an informed option rather than a universal requirement. The reasons to consider it, and the reasons it may not suit you, belong in the same discussion.

Management of Menopausal Symptoms: A Review The 2022 hormone therapy position statement of The North American Menopause Society

Ask which nonhormone option matches your goal and history

Nonhormone does not mean untested, and it does not mean free of side effects. Chrisandra Shufelt's 2023 Menopause Society panel recommended menopause-specific CBT, clinical hypnosis, selected SSRI/SNRI medicines, gabapentin and fezolinetant on its strongest evidence tier. SSRI and SNRI describe medicine classes that affect brain signaling; some are used for hot flashes as well as other conditions. The panel gave different evidence ratings to oxybutynin, weight loss and stellate ganglion block, an injection near nerves in the neck. Those options are not interchangeable, and the injection is a specialist procedure. A 2023 list also predates later approvals and safety changes. A prescriber can explain indication, interactions, monitoring and expected benefit for the option being considered; this is not a menu to combine yourself.

The 2023 nonhormone therapy position statement of The North American Menopause Society Nonhormone Treatments for Hot Flashes and Night Sweats Chrisandra L. Shufelt — official professional profile

Review safety requirements for medicines that target hot flashes

Fezolinetant, sold as VEOZAH, blocks a neurokinin-3 receptor involved in temperature regulation rather than supplying estrogen. The FDA added a boxed warning for rare serious liver injury in December 2024. Its safety communication describes liver bloodwork before treatment, monthly for the first three months, then at months six and nine, and instructions to stop the medicine and seek medical attention if liver-injury symptoms develop. Yellow skin or eyes, dark urine or new abdominal pain are examples to discuss promptly. Elinzanetant, sold as LYNKUET, blocks neurokinin-1 and -3 receptors; the FDA approved it on October 24, 2025 for moderate-to-severe menopausal heat. Its approval label also requires liver assessment and warns about drowsiness, daytime impairment, interactions and pregnancy. 'Nonhormonal' describes mechanism, not a safety guarantee.

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause VEOZAH (fezolinetant) tablets — prescribing information, revised December 2024 Drug Trials Snapshots: LYNKUET LYNKUET (elinzanetant) capsules — prescribing information, revised October 2025

Read a new approval through the comparison it tested

The FDA's LYNKUET snapshot describes two main efficacy trials in postmenopausal women with at least fifty moderate-to-severe hot flashes per week. At twelve weeks, the drug groups averaged about 3.2 fewer daily episodes than placebo after adjustment for baseline and trial factors. Both drug and placebo groups improved, so the extra difference is more informative than the drug group's change alone. The trials were not a head-to-head comparison with hormone therapy or fezolinetant. The FDA's tables describe participants aged 40–65, leaving older adults outside that reported age range; some racial groups had too few participants for confident subgroup conclusions. Approval establishes a tested option for a defined use. It does not establish that this is the best treatment for every stage, age or medical history.

Drug Trials Snapshots: LYNKUET

Why hormone advice can sound contradictory

Timing, formulation, route and duration are genuine decision questions. They should stay distinct from public slogans about mandatory treatment or a lifetime ban.

Read the WHI answer with the regimen and prevention question attached

The Women's Health Initiative's 2002 combined-hormone trial enrolled 16,608 postmenopausal women aged 50–79, with a mean age around 63. It compared a daily oral regimen of conjugated equine estrogen, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, with placebo. The trial stopped after an average 5.2 years because the overall prevention balance favored harm: more coronary events, stroke, pulmonary embolism and invasive breast cancer, alongside fewer hip fractures and colorectal cancers. All-cause mortality was not affected during that trial. Those findings matter. They are not a trial of every modern hormone product or of every younger person seeking symptom relief. JoAnn Manson's 2024 review preserves the conclusion against using hormones for broad chronic-disease prevention while allowing treatment for bothersome heat in suitable early-menopause candidates.

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial The Women's Health Initiative Randomized Trials and Clinical Practice: A Review

Compare absolute risk as well as relative risk

A relative risk describes a proportional difference; absolute risk describes how many people experience an event. The same proportional increase can produce more additional events in an older group with a higher starting risk. Manson's thirteen-year WHI overview found lower absolute adverse-event rates in younger participants than in older participants, with important differences between regimens. The age analyses refine the conversation; they are not a separate trial proving that every modern regimen prevents disease when started early. The original combined trial reported about eight additional invasive breast cancers per 10,000 person-years with its regimen. That figure belongs to its population and follow-up, rather than becoming your own annual risk. Ask for the baseline risk, the additional events and the time horizon relevant to the proposed product.

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial

Keep estrogen-alone and combined-therapy findings separate

WHI assigned women with a uterus to the combined estrogen/progestin trial and women with a prior hysterectomy to the estrogen-alone trial. Manson's 2013 cumulative analysis found higher invasive breast-cancer incidence with the combined regimen and lower incidence with the studied estrogen-alone regimen than with placebo. These are different trial populations and treatments, not permission to use estrogen alone when the uterus is present. Systemic estrogen can stimulate the endometrium, the uterine lining, so appropriate endometrial protection is needed, usually with a progestogen. A progestogen is a medicine with progesterone-like protective effects. The breast findings do not settle uterine safety. In a visit, identify the actual regimen and why its components are needed before comparing headline claims about 'hormones.'

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials Deciding About Hormone Therapy Use Menopause Topics: Hormone Therapy

Discuss route as a risk detail, with honest uncertainty

Transdermal estrogen enters through the skin, such as from a patch or gel; oral estrogen is swallowed. The Menopause Society notes evidence suggesting lower clot risk with transdermal treatment, while also explaining the lack of large randomized head-to-head trials for major clinical outcomes. A possible comparative advantage is not proof that patches eliminate stroke, clot or breast-cancer risk. Prior clots, stroke, heart disease, liver disease, unexplained bleeding and estrogen-sensitive cancers can change whether systemic therapy is appropriate at all. Mention vascular history, migraine history, medicines and surgery at the start of the consultation. A patch is still a prescription treatment, and changing route yourself bypasses the assessment that makes the comparison useful.

The 2022 hormone therapy position statement of The North American Menopause Society Menopause Topics: Hormone Therapy Chrisandra L. Shufelt — official professional profile

Review duration through a continuing reason for treatment

Some advice proposes a fixed stopping anniversary; other advice treats continued use as automatic. The Menopause Society instead ties longer use to documented indications, such as persistent vasomotor symptoms, with shared decisions and periodic reassessment. That leaves legitimate uncertainty about the best duration for different people and products. It does not make five years on treatment a universal stop rule or promise that indefinite treatment is risk-free. NICE recommends an initial treatment review at three months and subsequent annual review, with earlier review when symptoms, side effects or other concerns warrant it. Revisit the benefit you actually notice, new health conditions, the product and dose, and the reason to continue. A follow-up is part of care, not evidence that the first decision failed.

The 2022 hormone therapy position statement of The North American Menopause Society Menopause: identification and management — Recommendations (NG23)Monica Christmas — official professional profile

Interpret a changed warning label without erasing individual risk

On February 12, 2026 the FDA announced approved labeling changes for an initial six menopausal hormone products, removing cardiovascular, breast-cancer and probable-dementia risk statements from their boxed warnings. This is a regulatory labeling change affecting specified products; it is not proof that all formulations have become risk-free or that the same label change applies to every product. Clinical evidence, the rest of the product label and your own contraindications still matter. The distinction also helps resolve apparent conflicts between an older leaflet and a newer announcement. Ask the prescriber or pharmacist to review the current label for the exact medicine. A warning's position on the label does not by itself establish a new indication for lifelong disease prevention.

FDA Approves Labeling Changes to Menopausal Hormone Therapy Products The Women's Health Initiative Randomized Trials and Clinical Practice: A Review

What helps when nights stay broken?

Night sweats and insomnia can overlap. A useful assessment does not require one to explain the other completely.

Use the insomnia trial to understand what structured care can change

Susan McCurry and colleagues randomized 106 peri- or postmenopausal women aged 40–65 with insomnia and at least two daily hot flashes to six telephone CBT-I sessions or menopause education. CBT-I means cognitive behavioral therapy for insomnia: structured work on sleep timing, time in bed, habits and thoughts that sustain insomnia. After eight weeks, insomnia-severity scores fell by 9.9 points with CBT-I versus 4.7 with education; group differences remained at 24 weeks. Hot-flash counts did not differ, although interference improved. Better sleep did not require every heat episode to disappear. This was one selected, largely White study population, not a trial of every app or a proof that casual bedtime tips are equivalent. Ask about access to structured insomnia care rather than trying to recreate the trial's sleep restrictions alone.

Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial Susan M. McCurry — official professional profile

Keep breathing, mood and daytime function in the assessment

Repeated breathing pauses or gasping, loud snoring and unintended daytime sleepiness point toward a different sleep question from difficulty falling back asleep. NHLBI explains that sleep apnea can present with insomnia or fatigue in women as well as more familiar snoring symptoms. Depression, anxiety, medicines and other conditions can also belong in a clinical sleep history. Pauline Maki's menopause research examines mood and cognition, while Joffe's work connects midlife sleep and vasomotor symptoms. Those research connections support asking about the whole pattern; they do not diagnose the cause of your tiredness or a memory lapse. When heat treatment helps but sleep remains poor, the remaining problem is worth assessing on its own merits.

Sleep Apnea — Symptoms Pauline M. Maki — official professional profile Hadine Joffe — official professional profile

How bone and strength fit into midlife care

Feeling stronger, improving a density measurement and preventing a fracture are related but different outcomes.

Understand why bone health deserves attention during the transition

Bone is living tissue that is continually renewed. Cells remove old material and other cells replace it. The Menopause Society's osteoporosis statement explains that estrogen decline can accelerate removal beyond replacement around the transition, producing a period of faster bone loss. This can happen even when someone feels well. Bone strength depends on density and structure, while whether a fall becomes a fracture also depends on other factors. A density test, a medicine and an exercise session therefore address overlapping rather than identical parts of the problem. Hormone therapy can prevent bone loss in suitable users, but established osteoporosis needs its own management discussion. A person who is active may still need fracture-risk assessment; a person with low density may still benefit from suitably adapted activity.

Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society Postmenopausal Osteoporosis — MenoNote

Use risk and age to guide the bone-screening conversation

Bone mineral density measures how much mineral is present in a defined area of bone. A DXA scan is a low-dose X-ray test commonly used to measure it. Lower density can help identify osteoporosis, a condition associated with greater fracture risk, but density alone does not describe every reason a person may break a bone. USPSTF's 2025 recommendation is to screen women 65 or older, and postmenopausal women under 65 who are at increased risk after a clinical risk assessment. Factors include low body weight, a parent's hip fracture, smoking and excess alcohol use. This recommendation is for screening; people with known osteoporosis or a fragility fracture need assessment and management rather than a first-screening rule. Ask whether the recommendation fits your history.

Osteoporosis to Prevent Fractures: Screening

Read heavy-lifting evidence together with its supervision

Belinda Beck and colleagues' LIFTMOR trial studied 101 screened postmenopausal women with low bone mass for eight months. It compared a twice-weekly, thirty-minute supervised program of high-intensity resistance and impact training with lower-intensity home exercise. The research protocol included five sets of five repetitions above 85% of a one-repetition maximum, meaning the greatest weight a person could lift once. Spine density increased about 2.9% in the supervised group versus a 1.2% decline in controls, with better functional performance and one reported minor back spasm. These details are the study exposure, not your starting workout. The short trial measured density and function, not proof of fewer lifetime fractures. Screening, coaching and progression were part of the intervention; unsupervised heavy lifting is a different exposure.

High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial Belinda R. Beck — official professional profile

Choose repeatable movement for its own health outcomes

WHO's adult activity guidance includes strengthening all major muscle groups on at least two days each week, alongside aerobic activity; some activity is better than none. That population guidance is a useful direction, not a personal prescription or a demand to meet a heavy-lifting protocol immediately. Walking supports activity, while bone-targeted loading and resistance exercise ask different things of the body. Kohrt's research explains why estrogen, exercise, metabolism and body composition all belong in the midlife picture. If you already train, discuss whether your load, technique or supervision fits your health. If you are starting or have low bone mass, a qualified clinician or exercise professional can help adapt the work. Sudden severe pain or an injury needs assessment rather than a heavier session.

Physical activity Wendy M. Kohrt — official professional profile High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial

How to judge competing treatment promises

A disagreement in marketing is not automatically an unresolved scientific question. Ask what evidence would justify the specific promise.

Check the product evidence behind the word bioidentical

Bioidentical means that a molecule has the same chemical structure as a hormone made by the body. FDA-approved estradiol and micronized progesterone products can already meet that description. A compounded product is mixed to a prescription rather than approved as that finished formulation. The Endocrine Society says evidence does not establish that custom compounded hormone mixtures are safer or more effective, and warns about inconsistent dose and purity. The FDA's account of the National Academies review identifies weak clinical evidence and limited oversight as public-health concerns. This is a product-testing and quality question, not a contest between 'natural' and 'synthetic' words. A documented need for compounding, such as an ingredient allergy, is a clinician-pharmacy decision. The label alone does not justify replacing a regulated product.

Compounded Bioidentical Hormone Therapy National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy

Ask what a saliva test has been shown to predict

A saliva hormone panel can look precise because it produces numbers and a customized-looking recipe. Precision of presentation is different from demonstrated clinical usefulness. The Endocrine Society explains that hormone levels vary with physiology and the way medicines are absorbed and processed, and that evidence does not validate saliva-based customization as a reliable dosing method. This is separate from a clinician ordering a test for a specific diagnostic question. Jen Gunter's public education helps readers recognize such gaps between a convincing story and tested medicine, but the supporting authority here is the professional statement. Bring symptoms, history and treatment goals to the prescriber. Ask what outcome the test-guided approach improves over ordinary care, and whether that comparison has actually been studied.

Compounded Bioidentical Hormone Therapy Jen Gunter — official professional profile

Keep exercise and comfort strategies tied to the result they can deliver

A fan, clothing changes, walking or yoga may make an episode or a day more manageable. The Menopause Society's 2023 evidence review did not recommend exercise, yoga, cooling or trigger-avoidance lists as proven vasomotor treatments. That is an outcome-specific conclusion, not a reason to abandon activity or something that improves your comfort. WHO's guidance still supports movement for health, and LIFTMOR tested loading for bone. Public advice becomes misleading when it turns those benefits into a guarantee that heat will stop. You can keep a helpful routine while seeking evidence-based symptom care if needed. Improvement in muscle or comfort does not establish a reduction in the frequency of hot flashes.

The 2023 nonhormone therapy position statement of The North American Menopause Society Physical activity Hot Flashes

Compare herbal promises with supported nonhormone choices

Black cohosh, soy extracts and mixed 'menopause support' products are often presented as gentler substitutes for treatment. The 2023 society review did not recommend supplements and herbal remedies for vasomotor symptoms because adequate, consistent benefit was not established. A soy food in an ordinary diet is a different question from using an extract as a hot-flash treatment. Supplements can have adverse effects and interactions; 'natural' does not answer those questions. Show a clinician or pharmacist the ingredients rather than assuming a blend's marketing name describes what it contains. If you prefer to avoid hormones, ask about the named nonhormone options with evidence. Heavy bleeding or severe sleep disruption deserves assessment while that choice is being considered.

The 2023 nonhormone therapy position statement of The North American Menopause Society Nonhormone Treatments for Hot Flashes and Night Sweats

Check the claim before acting on it

These verdicts concern the statement as written. Read the matching explanation above for the finding and its limits.

Use the twelve-month marker with its exceptions

Claim: 'Menopause means periods have stopped for twelve months.' Verdict: established for natural menopause when another cause or hormonal treatment does not explain the absence. Surgery and younger age can require a different assessment. The marker names a stage retrospectively; it does not decide whether symptoms deserve care before or after that point.

Definition and Stages

Allow a longer course for frequent heat

Claim: 'Frequent hot flashes usually last only a year or two.' Verdict: not supported as written. SWAN's median was 7.4 years among women with frequent symptoms. Some courses are shorter, others much longer. A group estimate corrects the fixed timer but does not determine your last episode.

Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition

Make hormone therapy an individual choice

Claim: 'Every woman in menopause should take hormone therapy.' Verdict: not supported as written. Treatment depends on symptoms, indications, history, contraindications and preferences. Hormones are an effective option for heat and have bone effects; those benefits do not create a universal mandate or a general prescription for lifelong disease prevention.

Deciding About Hormone Therapy Use The Women's Health Initiative Randomized Trials and Clinical Practice: A Review

Keep the WHI conclusion attached to what it tested

Claim: 'The WHI proved that no one should ever take hormones.' Verdict: not supported as written. The trials raised important regimen-specific risks for prevention. Current interpretation still allows symptom treatment in suitable women near menopause. Neither discarding the trial nor turning it into a lifetime ban faithfully represents the evidence.

The Women's Health Initiative Randomized Trials and Clinical Practice: A Review

Separate activity benefits from a heat-treatment guarantee

Claim: 'Exercise is a proven treatment for hot flashes.' Verdict: not supported as written. The society review did not recommend exercise as vasomotor therapy. Muscle, function and bone remain worthwhile reasons for activity. Choosing it for those reasons does not require claiming that it will switch off heat.

The 2023 nonhormone therapy position statement of The North American Menopause Society Physical activity

Require evidence for a custom-product safety promise

Claim: 'Custom compounded bioidentical hormones are safer than approved products.' Verdict: not supported as written. The National Academies assessment found inadequate rigorous evidence and quality-oversight concerns. Body-identical molecules also exist in approved products. A custom label or saliva-derived recipe does not establish a safety advantage.

National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy

Recognize structured insomnia care as a tested option

Claim: 'CBT-I can improve insomnia during the menopause transition.' Verdict: established. McCurry's randomized trial found better insomnia outcomes than menopause education through 24 weeks in women with insomnia and hot flashes. This supports the possibility of benefit; it is not a guarantee or a substitute for investigating breathing pauses.

Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial

010

When to seek assessment promptly

A diary helps an appointment. It should never postpone assessment of concerning symptoms.

Have new or unusual bleeding assessed

Bleeding or spotting after natural menopause should be reported even if it happens only once or is a small amount. NHS guidance explains that it is often not serious but can sometimes signal a condition needing treatment, including cancer. Very heavy or unusually frequent bleeding during the transition also deserves assessment; it should not automatically be attributed to hormone fluctuation. HRT adds another distinction: some regimens intentionally produce scheduled bleeding, and NICE's April 2026 guidance notes that unscheduled bleeding can occur early after starting or changing systemic HRT. Beyond the specified adjustment periods, prompt medical help is advised. Discuss any new, persistent or concerning bleeding with the prescriber rather than deciding for yourself that it is expected or waiting out a rule from this article.

Postmenopausal bleeding Heavy periods Menopause: identification and management — Recommendations (NG23)

Use emergency help for sudden severe symptoms

Chest pain, fainting, sudden breathlessness or one-sided weakness should not be dismissed as a hot flash or ordinary midlife change. NIH heart-attack guidance and CDC stroke guidance emphasize prompt emergency assessment for relevant warning symptoms; call local emergency services, including 911 in the United States, when they occur. Severe bleeding with collapse or marked weakness also needs urgent help. This distinction protects the usefulness of ordinary symptom tracking: gradual patterns can inform a scheduled visit, while sudden severe changes need immediate attention. A page cannot determine which diagnosis explains the event. Do not wait to finish a diary or see whether a supplement, hormone dose or workout changes it.

Heart Attack — Symptoms Signs and Symptoms of Stroke Heavy periods

Use this reading to prepare for care

This is a reading companion, not a diagnosis, hormone prescription, or clinic visit. Persistent or bothersome heat, night sweats, broken sleep, early period stop, or worry about bone belong with a qualified clinician who can take a history and tailor care. After more than a year without a period, new bleeding or spotting needs prompt medical review. Periods that stop before 45, very heavy or closely stacked bleeding, and sudden severe symptoms also need a person, not a page. Do not start, stop, or change hormone therapy, other medicines, or a training plan from this text. Chest pain, fainting, one-sided weakness, or sudden breathlessness need emergency care. This page does not treat one body or promise an outcome.

Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

Menopause: identification and management — Recommendations (NG23)Definition and Stages Postmenopausal bleeding Heart Attack — Symptoms Signs and Symptoms of Stroke

011

Bring one clear question to your next visit

Choose the problem that matters most, while mentioning the others that may affect the decision.

Bring four lines that tell the clinician what has changed

Write a brief account of your cycle pattern, daytime heat or night sweats, sleep and daytime function, and the issue you want help with first. Add current medicines and supplements, relevant surgery, and any fracture, clot, cancer, liver or cardiovascular history. This translates the clinical-history approach used by NICE into a practical visit aid; it is not a diagnostic checklist. You might bring, 'My cycles have changed, heat wakes me, and I want to understand sleep and treatment options.' Ask what else should be assessed and which treatment outcome would count as worthwhile improvement. You do not need to resolve the hormone debate before requesting a conversation.

Menopause: identification and management — Recommendations (NG23)Deciding About Hormone Therapy Use Stephanie S. Faubion — official professional profile

Try a short diary that records interference

For a few ordinary weeks, note bleeding dates, a rough heat count, night sweats and whether they interrupted activity or sleep. Use simple words rather than treating the diary as a research-grade instrument. The field distinguishes frequency from interference, so include what you could not do or how long returning to sleep took. Bring what you have even if recording is incomplete. This is a suggested communication aid drawn from the kinds of outcomes researchers measure, not a validated home test or a requirement to delay care. New postmenopausal bleeding, very heavy bleeding or sudden severe symptoms belong in the care pathways above.

Hot Flashes CBT effective in treating menopause symptoms Postmenopausal bleeding

Try a specific question about sleep care

If insomnia is the main problem, ask where you can access CBT-I and whether a separate sleep assessment is indicated. Mention heat, gasping or breathing pauses, mood and medicines so the clinician can consider overlapping causes. McCurry's research supports structured care delivered by telephone in a defined group, rather than the idea that everyone must reach an in-person specialist before anything can help. Availability, cost and the suitability of a program still need checking locally. If heat improves but sleep does not, bring that result back; it helps clarify the next question. For how people talk about sleep hours, see STUDself at /self/. Its experience map does not replace clinical sleep assessment.

Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial Sleep Apnea — Symptoms Susan M. McCurry — official professional profile

Try a specific question about bone and supervised activity

Ask whether bone screening is due for your age and risk, and which kind of strength or impact activity fits your current health. Say what you already do; suitable progression is more useful than copying a study's maximum load. The screening recommendation and lifting trial answer different questions, so requesting one conversation does not commit you to either a scan or a high-intensity program. Agree on what symptoms or changes would prompt reassessment. For lifting after 40, see STUDfit at /fit/ for the community discussion. Keep exercise as health work, symptom treatment as a reviewed choice, and follow-up as an ordinary part of care.

Osteoporosis to Prevent Fractures: Screening High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial Physical activity

References for this topic

Sources and context

Menopause ↗
id
menopause--who-menopause — Menopause
kind
official
accessed at
2026-10-01
supports
Explains ovarian follicular loss, the twelve-month definition of natural menopause, variable symptoms and perimenopause.
limitations
Public education rather than a diagnostic or treatment algorithm.
original id
who-menopause
Menopause — Endocrine Library ↗
id
menopause--endo-menopause — Menopause — Endocrine Library
kind
professional
accessed at
2026-10-01
supports
Explains fluctuating hormones, changing cycle patterns and the role of clinical history in assessing atypical symptoms. Nanette Santoro is among its named clinical editors.
limitations
Page last updated January 24, 2022. Used for basic explanation, not an up-to-date medicine list or its simplified causal claims about mood.
original id
endo-menopause
Menopause — Symptoms and causes ↗
id
menopause--mayo-menopause — Menopause — Symptoms and causes
kind
professional
accessed at
2026-10-01
supports
Gives an average U.S. menopause age of 51 and distinguishes hysterectomy with ovaries remaining from removal of the ovaries.
limitations
A public summary; individual variation and other possible causes still require clinical assessment.
original id
mayo-menopause
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging ↗
id
menopause--straw-2012 — Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging
kind
guideline
accessed at
2026-10-01
supports
Defines the persistent seven-day cycle difference, sixty-day gap, late-transition duration and endpoint of perimenopause used in reproductive-aging staging.
limitations
Research and clinical staging consensus rather than home diagnosis; medication-masked bleeding and special populations need different assessment.
original id
straw-2012
Definition and Stages ↗
id
menopause--cms-stages — Definition and Stages
kind
professional
accessed at
2026-10-01
supports
Defines menopause retrospectively, distinguishes stage from symptoms, and explains when medical interventions or other causes complicate the definition.
limitations
Professional overview, not a personalized diagnostic test. Population definitions should not delay abnormal-bleeding care.
original id
cms-stages
Menopause: identification and management — Recommendations (NG23) ↗
id
menopause--nice-ng23 — Menopause: identification and management — Recommendations (NG23)
kind
guideline
accessed at
2026-10-01
supports
Sections 1.3.1–1.3.6 address clinical identification and testing; sections 1.8.4–1.8.5 address bleeding after systemic HRT; section 1.9 covers treatment review. The April 2026 bleeding guidance distinguishes the first six months after starting HRT and the first three months after a dose or preparation change from bleeding beyond those intervals, when prompt help is advised.
limitations
UK clinical guidance, not U.S. prescribing instructions. Full guideline/evidence collection not read cover to cover. Expected bleeding does not mean all bleeding can be ignored.
original id
nice-ng23
Evidence-based guideline: Premature Ovarian Insufficiency ↗
id
menopause--poi-guideline — Evidence-based guideline: Premature Ovarian Insufficiency
kind
guideline
accessed at
2026-10-01
supports
International guidance on before-40 POI, early menopause 40–44, intermittent ovarian activity in nonsurgical POI, distinct health/fertility needs and HT through usual menopause age. Current page title marks 2025; literature search ended January 30, 2024.
limitations
Many POI-specific options have limited evidence; clinician assessment required. This article uses it to explain the condition and the need for individualized care.
original id
poi-guideline
Heavy periods ↗
id
menopause--nhs-heavy-bleeding — Heavy periods
kind
official
accessed at
2026-10-01
supports
Explains symptoms and assessment of heavy periods and bleeding changes.
limitations
Public education; no home bleeding diagnosis or treatment algorithm. Urgent symptoms still require clinical assessment.
original id
nhs-heavy-bleeding
Hot Flashes ↗
id
menopause--society-hot-flashes — Hot Flashes
kind
professional
accessed at
2026-10-01
supports
Explains hot-flash and night-sweat definition, variation and symptom-management questions.
limitations
Public education. Comfort suggestions are not upgraded to trial-proven vasomotor therapy.
original id
society-hot-flashes
Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition ↗
id
menopause--avis-duration — Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
kind
study
accessed at
2026-10-01
supports
Reports SWAN analysis of 1,449 frequent-symptom participants; 7.4-year median, 4.5 years after final period among 881; earlier onset and group duration differences.
limitations
Observational, self-reported symptoms on at least six of prior fourteen days; selected symptomatic population. Medians and group associations are not personal predictions or proof of causation.
original id
avis-duration
Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial ↗
id
menopause--mccurry-cbti — Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial
kind
study
accessed at
2026-10-01
supports
Reports 106 participants, six telephone sessions, insomnia-score changes 9.9 versus 4.7 at eight weeks, sustained differences at 24 weeks, unchanged between-group flash frequency.
limitations
Single-site, selected largely White group; no apnea treatment, app equivalence, permanent cure or self-directed sleep-restriction plan claimed.
original id
mccurry-cbti
Hadine Joffe — official professional profile ↗
id
menopause--p-joffe — Hadine Joffe — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD, MSc; Chair and Chief of Psychiatry, Beth Israel Deaconess Medical Center. Public institutional role and authored menopause/sleep research bring mood, insomnia and heat into one assessable picture. Research findings are supported by the studies and guidelines cited separately.
limitations
Current role is BIDMC; older Brigham/Connors affiliations in prior publications are historical. Research does not diagnose a reader.
original id
p-joffe
Sleep Apnea — Symptoms ↗
id
menopause--nhlbi-apnea — Sleep Apnea — Symptoms
kind
official
accessed at
2026-10-01
supports
Explains why breathing pauses/gasping/snoring, daytime symptoms and presentation in women justify a separate assessment.
limitations
Symptom education, not home diagnosis. Sleep-study and treatment instructions excluded.
original id
nhlbi-apnea
Osteoporosis to Prevent Fractures: Screening ↗
id
menopause--uspstf-bone — Osteoporosis to Prevent Fractures: Screening
kind
guideline
accessed at
2026-10-01
supports
The January 2025 recommendation addresses women 65+; younger postmenopausal women at increased risk following clinical assessment; DXA; risk factors and exclusions.
limitations
Population screening guidance excludes known osteoporosis/fragility-fracture cases. Does not prescribe treatment or give a personal FRAX threshold.
original id
uspstf-bone
Wendy M. Kohrt — official professional profile ↗
id
menopause--p-kohrt — Wendy M. Kohrt — official professional profile
kind
professional
accessed at
2026-10-01
supports
PhD; Distinguished Professor in Geriatric Medicine and Nancy Anschutz Chair in Women's Health Research, University of Colorado Anschutz. University profile and public muscle-health education explain how exercise and estrogen affect midlife physiology. Research findings are supported by the studies and guidelines cited separately.
limitations
Physiology research does not establish one gym prescription or make exercise a vasomotor treatment.
original id
p-kohrt
High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial ↗
id
menopause--liftmor-2018 — High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial
kind
study
accessed at
2026-10-01
supports
The primary abstract describes 101 screened participants in an eight-month supervised trial, including five sets of five repetitions above 85% of one-repetition maximum, changes in spine density and one minor back spasm.
limitations
This account relies on the abstract; full text was unavailable for review. The small, selected and supervised study does not establish a reduction in fractures or the safety of unsupervised lifting.
original id
liftmor-2018
Management of Menopausal Symptoms: A Review ↗
id
menopause--crandall-review — Management of Menopausal Symptoms: A Review
kind
review
accessed at
2026-10-01
supports
The 2023 review abstract reports 50%–75% VMS prevalence during transition; approximate 75% average frequency reduction with systemic estrogen; treatment and prevention distinction.
limitations
Abstract inspected, not paywalled full text; pooled estimates, not individual benefit or head-to-head ranking. The discussion here concerns vasomotor symptoms.
original id
crandall-review
CBT effective in treating menopause symptoms ↗
id
menopause--menos-trials — CBT effective in treating menopause symptoms
kind
official
accessed at
2026-10-01
supports
The investigators' institutional report describes MENOS1 (96 breast-cancer survivors) and MENOS2 (140 otherwise healthy women): improved problem ratings through 26 weeks.
limitations
An institutional trial report rather than a review of the complete journal methods; it does not support a guarantee of no side effects.
original id
menos-trials
Myra S. Hunter — official professional profile ↗
id
menopause--p-hunter — Myra S. Hunter — official professional profile
kind
professional
accessed at
2026-10-01
supports
PhD; Emeritus Professor of Clinical Health Psychology, King's College London. Public biography describes menopause-focused CBT trials, books and self-help manuals. Research findings are supported by the studies and guidelines cited separately.
limitations
CBT does not mean symptoms are imagined, nor does it replace assessment or every other treatment.
original id
p-hunter
The 2022 hormone therapy position statement of The North American Menopause Society ↗
id
menopause--society-ht-2022 — The 2022 hormone therapy position statement of The North American Menopause Society
kind
guideline
accessed at
2026-10-01
supports
Addresses routes, contraindications, bone benefits, age, timing and duration. It describes a generally favorable balance for suitable symptomatic women under 60 or within ten years of menopause onset, without contraindications.
limitations
2022 consensus, not a new trial or updated product label. Evidence varies by formulation and route; no large route-comparison outcome RCT claimed. Not all 28 pages read line by line.
original id
society-ht-2022
The 2023 nonhormone therapy position statement of The North American Menopause Society ↗
id
menopause--society-nonhormone-2023 — The 2023 nonhormone therapy position statement of The North American Menopause Society
kind
guideline
accessed at
2026-10-01
supports
Sets out recommended interventions and evidence tiers; exercise/yoga/cooling/supplement conclusions are specific to vasomotor outcomes.
limitations
Predates December 2024 fezolinetant boxed warning and October 2025 elinzanetant approval. No DIY prescribing, combination plan or assumption that nonhormone means harmless.
original id
society-nonhormone-2023
Nonhormone Treatments for Hot Flashes and Night Sweats ↗
id
menopause--society-nonhormone-handout — Nonhormone Treatments for Hot Flashes and Night Sweats
kind
professional
accessed at
2026-10-01
supports
Distinguishes supported nonhormone options from popular approaches.
limitations
Patient education; no guarantee, dosage plan or complete current-label review.
original id
society-nonhormone-handout
Chrisandra L. Shufelt — official professional profile ↗
id
menopause--p-shufelt — Chrisandra L. Shufelt — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD, MS; Mayo Clinic women's-health and cardiovascular-hormone researcher. Official research description and society guidance make nonhormone options and vascular questions accessible. Research findings are supported by the studies and guidelines cited separately.
limitations
The 2023 recommendations predate later drug approvals and safety changes; route evidence has randomized-trial limits.
original id
p-shufelt
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause ↗
id
menopause--fda-veozah-safety — FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
kind
official
accessed at
2026-10-01
supports
The December 16, 2024 boxed-warning update specifies liver tests before treatment, monthly for the first three months, and at months six and nine, plus an urgent response to liver-injury symptoms.
limitations
Historical safety communication as hosted October 1, 2026; not represented as latest complete prescribing label. Current exact product instructions remain prescriber's responsibility.
original id
fda-veozah-safety
VEOZAH (fezolinetant) tablets — prescribing information, revised December 2024 ↗
id
menopause--fda-veozah-label — VEOZAH (fezolinetant) tablets — prescribing information, revised December 2024
kind
official
accessed at
2026-10-01
supports
Contains the boxed liver-injury warning and monitoring requirements described in the safety update.
limitations
Explicitly December 2024 label, not claimed to be newest complete label; no dose recommendations in article.
original id
fda-veozah-label
Drug Trials Snapshots: LYNKUET ↗
id
menopause--fda-lynkuet-snapshot — Drug Trials Snapshots: LYNKUET
kind
official
accessed at
2026-10-01
supports
Documents October 24, 2025 approval; OASIS efficacy participants and episode criteria; approximately 3.2 extra daily episodes reduced versus placebo at week twelve; age and subgroup limitations.
limitations
An original-approval snapshot rather than the latest label or a head-to-head treatment comparison. The age tables report a range of 40–65, while the summary gives a conflicting cutoff; this article uses the tabulated range. The snapshot's incorrect link to an unrelated drug label was excluded.
original id
fda-lynkuet-snapshot
LYNKUET (elinzanetant) capsules — prescribing information, revised October 2025 ↗
id
menopause--fda-lynkuet-label — LYNKUET (elinzanetant) capsules — prescribing information, revised October 2025
kind
official
accessed at
2026-10-01
supports
The original approval label describes NK1/NK3 mechanism, baseline and three-month liver assessment, daytime impairment, interactions and pregnancy contraindication.
limitations
Original approval label, not claimed newest complete label. No doses or self-management protocol proposed; current product assessment belongs to prescriber.
original id
fda-lynkuet-label
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial ↗
id
menopause--whi-2002 — Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
kind
study
accessed at
2026-10-01
supports
Reports 16,608 participants, ages 50–79, specific oral CEE/MPA doses, 5.2-year follow-up, stopped prevention trial, major harms/benefits and absolute breast-cancer excess.
limitations
One regimen and prevention population with mean age around 63; does not test every modern formulation or establish a universal ban. Selected relevant report sections inspected.
original id
whi-2002
The Women's Health Initiative Randomized Trials and Clinical Practice: A Review ↗
id
menopause--whi-review-2024 — The Women's Health Initiative Randomized Trials and Clinical Practice: A Review
kind
review
accessed at
2026-10-01
supports
The review abstract concludes that WHI does not support HT for cardiovascular/other chronic-disease prevention; symptom care in suitable early-menopause women remains appropriate.
limitations
Abstract inspected, not entire paywalled review. Does not establish a preventive indication for all formulations or prescribe for visitors.
original id
whi-review-2024
Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials ↗
id
menopause--whi-followup-2013 — Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials
kind
study
accessed at
2026-10-01
supports
Reviews thirteen years of findings from both randomized trials, including combined/estrogen-alone breast patterns and absolute-event differences by age.
limitations
Age subgroup interpretation and extended follow-up have limits; not a new randomized test of early modern therapy. Different regimens and uterine-status populations remain separate.
original id
whi-followup-2013
Deciding About Hormone Therapy Use ↗
id
menopause--society-ht-handout — Deciding About Hormone Therapy Use
kind
professional
accessed at
2026-10-01
supports
A two-page society handout about symptom decisions, uterus/progestogen considerations and individualized review.
limitations
2025 educational handout, not a prescription or evidence of a universal duration rule.
original id
society-ht-handout
Menopause Topics: Hormone Therapy ↗
id
menopause--society-ht-patient — Menopause Topics: Hormone Therapy
kind
professional
accessed at
2026-10-01
supports
Explains systemic treatment, endometrial protection when uterus present and possible route-related clot-risk difference.
limitations
Public simplifications and exact cancer-year claims are not reproduced as universal safety thresholds. Original trials and position statement govern nuanced comparison.
original id
society-ht-patient
Monica Christmas — official professional profile ↗
id
menopause--p-christmas — Monica Christmas — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD; University of Chicago obstetrician-gynecologist, director of its menopause program and Center for Women's Integrated Health. Official physician profile and public Q&A explain how symptom care differs across patients. Research findings are supported by the studies and guidelines cited separately.
limitations
Her inclusion does not imply endorsement of this article or establish one treatment duration for all readers.
original id
p-christmas
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products ↗
id
menopause--fda-ht-labels-2026 — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
kind
official
accessed at
2026-10-01
supports
The February 12, 2026 announcement describes initial six products' approved boxed-warning changes and distinction from November 2025 request.
limitations
Regulatory announcement, not a new trial, a record of all subsequent product changes or proof of absent risk. Broader promotional prevention interpretations not adopted.
original id
fda-ht-labels-2026
Susan M. McCurry — official professional profile ↗
id
menopause--p-mccurry — Susan M. McCurry — official professional profile
kind
professional
accessed at
2026-10-01
supports
PhD; Research Professor Emeritus, University of Washington School of Nursing. Official profile describes clinical psychology and sleep research in older adults and people with coexisting conditions, including menopause. Research findings are supported by the studies and guidelines cited separately.
limitations
Selected clinical trial does not establish equivalence of an app, unsupervised sleep restriction or apnea treatment.
original id
p-mccurry
Pauline M. Maki — official professional profile ↗
id
menopause--p-maki — Pauline M. Maki — official professional profile
kind
professional
accessed at
2026-10-01
supports
PhD; Professor of Psychiatry, Psychology and Obstetrics and Gynecology; Senior Director of Research, UIC Center for Research on Women and Gender. Official profile describes menopause, cognition and mood research and professional guideline contributions. Research findings are supported by the studies and guidelines cited separately.
limitations
Cognitive complaints and depression need their own assessment; no dementia-prevention indication is inferred.
original id
p-maki
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society ↗
id
menopause--society-bone-2021 — Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
kind
guideline
accessed at
2026-10-01
supports
Explains bone remodeling imbalance with estrogen decline; density versus strength/fracture; individualized management.
limitations
2021 North American consensus; no personal osteoporosis-treatment algorithm. Current screening age/risk recommendations sourced separately to USPSTF 2025.
original id
society-bone-2021
Postmenopausal Osteoporosis — MenoNote ↗
id
menopause--society-bone-handout — Postmenopausal Osteoporosis — MenoNote
kind
professional
accessed at
2026-10-01
supports
Explains bone risk and osteoporosis for patients.
limitations
Educational summary, not an individualized scan, drug or exercise decision.
original id
society-bone-handout
Belinda R. Beck — official professional profile ↗
id
menopause--p-beck — Belinda R. Beck — official professional profile
kind
professional
accessed at
2026-10-01
supports
Professor of bone and exercise research, Griffith University. Official exercise-science team page describes bone-health research and its translation into clinical services. Research findings are supported by the studies and guidelines cited separately.
limitations
Small supervised trial is not proof of fracture prevention or safety of unsupervised lifting; clinical services are not themselves independent trials.
original id
p-beck
Physical activity ↗
id
menopause--who-activity — Physical activity
kind
official
accessed at
2026-10-01
supports
Describes adult aerobic and muscle-strengthening guidance, including work for major muscle groups on two or more days and the value of some activity over none.
limitations
Population recommendation, not a menopause-treatment trial or individual gym program; full guideline PDF not claimed read.
original id
who-activity
Compounded Bioidentical Hormone Therapy ↗
id
menopause--endo-compounding — Compounded Bioidentical Hormone Therapy
kind
guideline
accessed at
2026-10-01
supports
The 2019 statement addresses molecule definition, approved body-identical products, lack of superiority evidence, variable quality and unsupported saliva customization.
limitations
Position statement, not a new outcomes trial. Does not deny documented clinical compounding needs or adjudicate every pharmacy.
original id
endo-compounding
National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy ↗
id
menopause--fda-nasem — National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy
kind
official
accessed at
2026-10-01
supports
The FDA's summary of the independent July 2020 report describes lack of rigorous clinical safety/effectiveness evidence and limited oversight.
limitations
Official report summary, not complete 2020 book; absence of superiority evidence is not proof that every compounded preparation always causes harm.
original id
fda-nasem
Jen Gunter — official professional profile ↗
id
menopause--p-gunter — Jen Gunter — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD; obstetrician-gynecologist and pain-medicine physician, as identified by TED. TED's official speaker biography and Body Stuff public education address menopause myths and treatment language. Research findings are supported by the studies and guidelines cited separately.
limitations
Public communication is not primary trial evidence. The cited TED biography supports the role described here; a current Kaiser affiliation was not established.
original id
p-gunter
Postmenopausal bleeding ↗
id
menopause--nhs-postmenopausal-bleeding — Postmenopausal bleeding
kind
official
accessed at
2026-10-01
supports
The NHS page, reviewed September 24, 2026, explains assessment needed even for one small episode, common benign causes and potential cancer relevance.
limitations
UK public triage information; not a cancer diagnosis, a universal HRT-bleeding rule or a U.S. referral-time guarantee.
original id
nhs-postmenopausal-bleeding
Heart Attack — Symptoms ↗
id
menopause--nhlbi-heart — Heart Attack — Symptoms
kind
official
accessed at
2026-10-01
supports
Explains warning symptoms and the need for prompt emergency help.
limitations
Does not mean every chest symptom is a heart attack; used for escalation, not diagnosis.
original id
nhlbi-heart
Signs and Symptoms of Stroke ↗
id
menopause--cdc-stroke — Signs and Symptoms of Stroke
kind
official
accessed at
2026-10-01
supports
The May 19, 2026 CDC guidance explains why sudden one-sided weakness and other stroke symptoms require immediate emergency help.
limitations
Used only for emergency escalation; no stroke risk score or differential diagnosis.
original id
cdc-stroke
Stephanie S. Faubion — official professional profile ↗
id
menopause--p-faubion — Stephanie S. Faubion — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD, MBA; Mayo Clinic internist and director of its Center for Women's Health. Mayo's public biography includes an accessible explanation of midlife symptoms and clinical education. Research findings are supported by the studies and guidelines cited separately.
limitations
A clinical leader's public explanation is not a prescription or a trial of every regimen.
original id
p-faubion
HRT guidance update UK — r/Menopause discussion ↗
id
menopause--question-hrt-cbt — HRT guidance update UK — r/Menopause discussion
kind
question_signal
accessed at
2026-10-01
supports
Discussion illustrates confusion about whether talking therapy complements or replaces hormones, and why symptom frequency, interference and treatment choice need to be distinguished.
limitations
Qualitative self-selected discussion, including unsupported prevention claims; no comment is factual medical authority or representative prevalence evidence.
original id
question-hrt-cbt
Hormone therapy recommendations — r/Menopause discussion ↗
id
menopause--question-guidance-access — Hormone therapy recommendations — r/Menopause discussion
kind
question_signal
accessed at
2026-10-01
supports
Discussion illustrates how people use professional recommendations when seeking care, informing the article's appointment preparation.
limitations
A qualitative source of reader questions, not medical evidence; treatment claims rely on the professional sources cited separately.
original id
question-guidance-access
JoAnn E. Manson — official professional profile ↗
id
menopause--p-manson — JoAnn E. Manson — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD, DrPH; Harvard professor of medicine and Brigham and Women's Hospital chief of preventive medicine. Harvard public-health writing and WHI reviews translate the prevention findings into clinical questions. Research findings are supported by the studies and guidelines cited separately.
limitations
WHI regimens and populations do not represent every modern therapy; public education is not individualized care.
original id
p-manson
Nanette F. Santoro — official professional profile ↗
id
menopause--p-santoro — Nanette F. Santoro — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD; E. Stewart Taylor Professor of Obstetrics and Gynecology, University of Colorado Anschutz. Public university research description and professional menopause education explain changing ovarian function. Research findings are supported by the studies and guidelines cited separately.
limitations
Fluctuating physiology cannot date one reader's final period or turn one blood test into a verdict.
original id
p-santoro
Rebecca C. Thurston — official professional profile ↗
id
menopause--p-thurston — Rebecca C. Thurston — official professional profile
kind
professional
accessed at
2026-10-01
supports
PhD; Pittsburgh Foundation Chair in Women's Health and Dementia and Distinguished Professor of Psychiatry, University of Pittsburgh. Official research biography and selected publications explain vasomotor symptoms in relation to daily life and health. Research findings are supported by the studies and guidelines cited separately.
limitations
Observational associations do not prove that treating flashes prevents cardiovascular disease.
original id
p-thurston
Siobán D. Harlow — official professional profile ↗
id
menopause--p-harlow — Siobán D. Harlow — official professional profile
kind
professional
accessed at
2026-10-01
supports
PhD; Professor Emerita of Epidemiology and Obstetrics and Gynecology, University of Michigan. Public research profile explains SWAN and the internationally used reproductive-aging staging system. Research findings are supported by the studies and guidelines cited separately.
limitations
Research stages provide a common language rather than a personal diagnostic algorithm.
original id
p-harlow
Carolyn J. Crandall — official professional profile ↗
id
menopause--p-crandall — Carolyn J. Crandall — official professional profile
kind
professional
accessed at
2026-10-01
supports
MD, MS; UCLA professor of medicine and internal-medicine physician. Official profile and JAMA clinical reviews explain treatment evidence without requiring a headline-level conclusion. Research findings are supported by the studies and guidelines cited separately.
limitations
Review estimates are group results, not personal efficacy promises; breast findings stay attached to the regimen.
original id
p-crandall
Nancy E. Avis — official professional profile / primary research authorship ↗
id
menopause--p-avis — Nancy E. Avis — official professional profile / primary research authorship
kind
professional
accessed at
2026-10-01
supports
PhD; SWAN investigator and lead author of the vasomotor-duration analysis. The primary report's accessible duration findings replace the common one- or two-year expectation. Research findings are supported by the studies and guidelines cited separately.
limitations
Primary-paper role verified; current faculty appointment is not claimed. Cohort medians do not predict one person's course.
original id
p-avis

Professional perspectives

Stephanie S. Faubion
MD, MBA; Mayo Clinic internist and director of its Center for Women's Health
Public usefulness
Mayo's public biography includes an accessible explanation of midlife symptoms and clinical education.
Contribution
Chaired the 2022 hormone-therapy advisory panel; helps distinguish symptom treatment from a mandate.
Scope and limits
A clinical leader's public explanation is not a prescription or a trial of every regimen.
Reviewed
2026-10-01
JoAnn E. Manson
MD, DrPH; Harvard professor of medicine and Brigham and Women's Hospital chief of preventive medicine
Public usefulness
Harvard public-health writing and WHI reviews translate the prevention findings into clinical questions.
Contribution
WHI intervention and follow-up work makes regimen, age and absolute risk visible.
Scope and limits
WHI regimens and populations do not represent every modern therapy; public education is not individualized care.
Reviewed
2026-10-01
Nanette F. Santoro
MD; E. Stewart Taylor Professor of Obstetrics and Gynecology, University of Colorado Anschutz
Public usefulness
Public university research description and professional menopause education explain changing ovarian function.
Contribution
Reproductive-aging and hormone-pattern research informs the clinical story behind cycle variation.
Scope and limits
Fluctuating physiology cannot date one reader's final period or turn one blood test into a verdict.
Reviewed
2026-10-01
Rebecca C. Thurston
PhD; Pittsburgh Foundation Chair in Women's Health and Dementia and Distinguished Professor of Psychiatry, University of Pittsburgh
Public usefulness
Official research biography and selected publications explain vasomotor symptoms in relation to daily life and health.
Contribution
Studies physiological hot flashes, sleep and cardiovascular-health relationships.
Scope and limits
Observational associations do not prove that treating flashes prevents cardiovascular disease.
Reviewed
2026-10-01
Hadine Joffe
MD, MSc; Chair and Chief of Psychiatry, Beth Israel Deaconess Medical Center
Public usefulness
Public institutional role and authored menopause/sleep research bring mood, insomnia and heat into one assessable picture.
Contribution
Coauthor of the MsFLASH insomnia trial; helps separate overlapping causes of a disrupted night.
Scope and limits
Current role is BIDMC; older Brigham/Connors affiliations in prior publications are historical. Research does not diagnose a reader.
Reviewed
2026-10-01
Pauline M. Maki
PhD; Professor of Psychiatry, Psychology and Obstetrics and Gynecology; Senior Director of Research, UIC Center for Research on Women and Gender
Public usefulness
Official profile describes menopause, cognition and mood research and professional guideline contributions.
Contribution
Makes mood and cognitive complaints part of a clinical assessment rather than an automatic hormone explanation.
Scope and limits
Cognitive complaints and depression need their own assessment; no dementia-prevention indication is inferred.
Reviewed
2026-10-01
Siobán D. Harlow
PhD; Professor Emerita of Epidemiology and Obstetrics and Gynecology, University of Michigan
Public usefulness
Public research profile explains SWAN and the internationally used reproductive-aging staging system.
Contribution
Led STRAW+10 staging, including the seven-day and sixty-day cycle criteria.
Scope and limits
Research stages provide a common language rather than a personal diagnostic algorithm.
Reviewed
2026-10-01
Chrisandra L. Shufelt
MD, MS; Mayo Clinic women's-health and cardiovascular-hormone researcher
Public usefulness
Official research description and society guidance make nonhormone options and vascular questions accessible.
Contribution
Led the 2023 nonhormone statement; studies cardiovascular effects of hormonal environments.
Scope and limits
The 2023 recommendations predate later drug approvals and safety changes; route evidence has randomized-trial limits.
Reviewed
2026-10-01
Carolyn J. Crandall
MD, MS; UCLA professor of medicine and internal-medicine physician
Public usefulness
Official profile and JAMA clinical reviews explain treatment evidence without requiring a headline-level conclusion.
Contribution
Synthesizes vasomotor treatments and investigates bone and breast outcomes in WHI.
Scope and limits
Review estimates are group results, not personal efficacy promises; breast findings stay attached to the regimen.
Reviewed
2026-10-01
Wendy M. Kohrt
PhD; Distinguished Professor in Geriatric Medicine and Nancy Anschutz Chair in Women's Health Research, University of Colorado Anschutz
Public usefulness
University profile and public muscle-health education explain how exercise and estrogen affect midlife physiology.
Contribution
Studies estrogen, activity, body composition and bone; supports separating strength goals from hot-flash relief.
Scope and limits
Physiology research does not establish one gym prescription or make exercise a vasomotor treatment.
Reviewed
2026-10-01
Belinda R. Beck
Professor of bone and exercise research, Griffith University
Public usefulness
Official exercise-science team page describes bone-health research and its translation into clinical services.
Contribution
LIFTMOR investigator who tested screened, supervised heavy loading for low bone mass.
Scope and limits
Small supervised trial is not proof of fracture prevention or safety of unsupervised lifting; clinical services are not themselves independent trials.
Reviewed
2026-10-01
Myra S. Hunter
PhD; Emeritus Professor of Clinical Health Psychology, King's College London
Public usefulness
Public biography describes menopause-focused CBT trials, books and self-help manuals.
Contribution
MENOS trials show how CBT can reduce the problem rating of heat even when episode frequency is a different outcome.
Scope and limits
CBT does not mean symptoms are imagined, nor does it replace assessment or every other treatment.
Reviewed
2026-10-01
Jen Gunter
MD; obstetrician-gynecologist and pain-medicine physician, as identified by TED
Public usefulness
TED's official speaker biography and Body Stuff public education address menopause myths and treatment language.
Contribution
Public communication helps distinguish 'bioidentical' molecules from marketing claims about compounded products.
Scope and limits
Public communication is not primary trial evidence. The cited TED biography supports the role described here; a current Kaiser affiliation was not established.
Reviewed
2026-10-01
Monica Christmas
MD; University of Chicago obstetrician-gynecologist, director of its menopause program and Center for Women's Integrated Health
Public usefulness
Official physician profile and public Q&A explain how symptom care differs across patients.
Contribution
Patient-centered menopause education supports reviewing purpose, benefit and risks over time.
Scope and limits
Her inclusion does not imply endorsement of this article or establish one treatment duration for all readers.
Reviewed
2026-10-01
Nancy E. Avis
PhD; SWAN investigator and lead author of the vasomotor-duration analysis
Public usefulness
The primary report's accessible duration findings replace the common one- or two-year expectation.
Contribution
SWAN longitudinal analysis of frequent vasomotor symptoms reports median duration and variation by timing and group.
Scope and limits
Primary-paper role verified; current faculty appointment is not claimed. Cohort medians do not predict one person's course.
Reviewed
2026-10-01
Susan M. McCurry
PhD; Research Professor Emeritus, University of Washington School of Nursing
Public usefulness
Official profile describes clinical psychology and sleep research in older adults and people with coexisting conditions, including menopause.
Contribution
Led the MsFLASH telephone-CBT-I trial showing sustained insomnia improvement without lower between-group flash frequency.
Scope and limits
Selected clinical trial does not establish equivalence of an app, unsupervised sleep restriction or apnea treatment.
Reviewed
2026-10-01

Keep this topic in view

Preserved original record

The earlier public profile is preserved separately from the current article. It may contain superseded wording and is not newly checked material.

Read the full original profile

slug

menopause

name

Menopause and the years around it

browse Line

Understand changing cycles, hot flashes, sleep, bone health, and hormone treatment.

photo

/learn/assets/topics/menopause.jpg

photo Alt

An adult sitting by a window with a mug, looking outward in ordinary daylight

aliases

perimenopause
hot flashes
night sweats
HRT
hormone therapy
menopause transition
vasomotor
midlife bone
menopause sleep
the change

family

body

heat

mid

talk

Sources

most Discussed

true

first Line

Menopause is recognized after twelve months without a menstrual period when another cause or hormonal treatment does not explain it. The surrounding transition can involve changing cycles, hot flashes, sleep problems and longer-term bone-health questions.

why Line

feel Words

perimenopause
peri
irregular
last period
twelve months
stage
hot flash
hot flush

common Picture

lead
Tell peri from menopause by the last period
why
Changing cycles and the final menstrual period belong to a transition that is named retrospectively. In STRAW+10, perimenopause begins with persistent cycle changes and includes the first twelve months after the final period. Menopause is recognized once that year without bleeding has passed, when another cause does not explain it. NICE often identifies the transition clinically in people aged 45 or over with typical symptoms, rather than through routine hormone tests. Hormonal contraception, surgery and younger age can make the calendar harder to interpret. Bringing a cycle and symptom history helps a clinician assess those differences.
lead
Make sense of heat that lasts years, not weeks
why
A hot flash is a sudden wave of heat, often in the face, neck, and chest, sometimes with flushing and sweat; a night sweat is the same event during sleep. Researchers call these vasomotor symptoms. Nancy Avis and colleagues in the Study of Women's Health Across the Nation followed midlife women with frequent symptoms and found a median total duration of 7.4 years, with 4.5 years after the final period among those with an observed last period. People who first had frequent heat while still cycling tended to have the longest course. Rebecca Thurston studies how these events sit in daily life and later health research; the duration finding is from SWAN, not a promise about one person. If heat is still interrupting work or sleep after the two-year folklore window, that pattern matches the cohort more than it contradicts it. Bring bothersome heat to a clinician rather than waiting for an automatic stop date.
lead
Get help when nights stay broken around the transition
why
Night sweats can wake a person, and some midlife insomnia continues even when heat is not the whole story. Hadine Joffe's research program treats sleep, mood, and thermoregulatory symptoms as related midlife problems rather than one slogan. In the MsFLASH trial, Susan McCurry and colleagues randomized 106 perimenopausal or postmenopausal women with insomnia and daily hot flashes to telephone cognitive behavioral therapy for insomnia or menopause education. Insomnia scores fell more with CBT-I, and the sleep gain lasted to 24 weeks; daily hot-flash counts did not differ, though interference from heat improved. CBT-I means a structured program of sleep timing, bed use, and thought-and-behavior work, not a pep talk. If a full-looking night still leaves you unrefreshed, or you cannot stay asleep, ask a clinician about insomnia care and about causes that need their own evaluation.
lead
Keep muscle and bone in the midlife week
why
After the last period, average bone mineral density falls faster for a stretch of years, and unused muscle is easier to lose. The Menopause Society 2022 hormone-therapy statement records that hormone therapy can prevent bone loss and fracture in appropriate users; that is a documented effect, not a requirement to take hormones. The U.S. Preventive Services Task Force recommends bone-density screening for women 65 and older and for younger postmenopausal women at increased fracture risk. Belinda Beck's LIFTMOR trial found that eight months of twice-weekly supervised high-intensity resistance and impact training improved lumbar-spine density and function versus a low-intensity home program in screened postmenopausal women with low bone mass. Wendy Kohrt studies how estrogen and exercise jointly affect midlife body composition. Strength work is a health practice with its own evidence. It is not a hot-flash cure and not a substitute for a fracture-risk conversation.

situation Quick Answers

- label
  Perimenopause
  value
  The transition of changing cycles, including the first twelve months after the final period in STRAW+10.
- label
  Menopause
  value
  Recognized after twelve months without a period when another cause or hormonal treatment does not explain it.
- label
  Frequent hot flashes and night sweats
  value
  Median total duration in SWAN: 7.4 years.
- label
  After the final period
  value
  Median 4.5 years among participants whose final period was observed; individual courses differ.
- label
  If they disrupt work or sleep
  value
  Bring the symptoms to a clinician instead of waiting for a fixed two-year stop date.
- label
  A useful care option
  value
  Ask about CBT-I—structured cognitive behavioral therapy for insomnia—and evaluation of other causes of broken sleep.
- label
  What the trial found
  value
  Sleep improved through 24 weeks; daily hot-flash counts did not differ, although heat interfered less.
- label
  Muscle and bone
  value
  Keep strength work in the week; supervised training has evidence for bone density and function in screened participants.
- label
  Bone-density screening
  value
  Recommended for women 65 and older and younger postmenopausal women at increased fracture risk.
- label
  Hormone therapy
  value
  Can prevent bone loss and fracture in appropriate users; it is one option to discuss, not a requirement.

picture Lead

Tell peri from menopause by the last period

watch For

what People Say

Name menopause after twelve quiet months. The National Institute on Aging says you know menopause has occurred when there has been no period or spotting for a full year; the U.S. average age is about 52, with a wide range. STRAW+10 places the final menstrual period at the center of staging and treats the twelve months after that last bleed as the close of perimenopause in ordinary speech. NICE tells clinicians not to rely on routine FSH tests to name the stage in otherwise healthy people 45 and over with typical symptoms, because hormone levels swing during the transition. Nanette Santoro has spent decades explaining that swing in SWAN and in clinic teaching. Use the calendar and the symptom story first. A single blood draw is not a verdict, and a page cannot date your last period for you.
Expect frequent heat to last years for many people. Vasomotor symptoms are the field name for hot flashes and night sweats. Avis reported a median 7.4 years of frequent symptoms in SWAN, not a two-year cap. African American women in that analysis had a longer median duration than other groups studied, which is a reminder that averages hide real differences. Thurston and Janet Carpenter have helped the field treat bother and interference as outcomes, not only a daily tally. Crandall, Mehta, and Manson estimated that about half to three-quarters of women have vasomotor symptoms during the transition. If heat is still present years after the last period, that can still be the transition rather than a personal failure. Duration is descriptive. It does not by itself decide treatment.
Treat hormone therapy as the strongest option for bothersome heat, not a requirement. The 2022 hormone-therapy position statement of The North American Menopause Society, now The Menopause Society, says hormone therapy remains the most effective treatment for vasomotor symptoms and has been shown to prevent bone loss and fracture. Stephanie Faubion chaired that advisory panel. Crandall's 2023 JAMA review estimated about a 75 percent reduction in vasomotor frequency with systemic estrogen, with or without a progestogen. JoAnn Manson's 2024 WHI review says hormone therapy is appropriate for bothersome vasomotor symptoms in early menopause for women without contraindications who want it, and is not supported as a way to prevent heart disease or other chronic disease. That is a bothersome-symptom option with named limits. It is not a rule that every midlife adult must take hormones.
Use recommended nonhormone options when hormones are not the path. Chrisandra Shufelt led The Menopause Society's 2023 nonhormone position statement. Recommended options with the strongest evidence ratings included cognitive-behavioral therapy, clinical hypnosis, selected SSRI and SNRI medicines, gabapentin, and fezolinetant, with oxybutynin, weight loss, and stellate ganglion block in lower-rated rows. Myra Hunter's menopause-specific CBT work is one reason CBT sits in that recommended list: it often reduces how much heat interferes with life. The same statement does not recommend herbal supplements, soy as treatment, acupuncture, or exercise as vasomotor therapy. A nonhormone path is a real field option for people who cannot take estrogen, prefer not to, or want something in addition. Medicine choice, dose, and contraindications belong with a prescriber.
Use structured insomnia care when sleep stays hard. Cognitive behavioral therapy for insomnia is a time-limited program that changes sleep schedule, time in bed, and the habits and thoughts that keep a person struggling for sleep. McCurry's MsFLASH trial showed larger insomnia-score drops with telephone CBT-I than with menopause education in women who also had hot flashes, with benefits still visible at six months. Joffe notes that vasomotor events contribute to awakenings and that the hormone environment may also relate to sleep disturbance after those events are accounted for. Treating only the flash does not automatically repair an insomnia pattern, and treating only sleep does not erase heat. If snoring with gasping, repeated unintended sleep, or a sudden change in function is present, that is a different evaluation. Ask for the matching kind of help.
Keep strength work and bone screening in view. World Health Organization adult guidance includes muscle-strengthening activity for major muscle groups on two or more days each week. That population target is not a personal program. USPSTF 2025 guidance recommends DXA screening for women 65 and older and for younger postmenopausal women at increased osteoporotic-fracture risk. LIFTMOR tested a short, supervised, heavy lifting and impact session twice a week in screened women with low bone mass and found better spine density and function than a low-intensity control. Kohrt’s work keeps estrogen, exercise, and body composition in the same midlife picture without turning one gym session into a hormone. Strength training supports muscle and can support bone when the loading and supervision fit the person. It does not replace fracture-risk care or guarantee a density number.

disputed Notes

Weigh hormone therapy by age, timing, and the reason for use. The 2002 WHI estrogen-plus-progestin trial, led for publication by Jacques Rossouw, enrolled postmenopausal women with a mean age in the early sixties and asked whether combined oral hormones prevented chronic disease. Overall risks exceeded benefits for that prevention question. Later age-stratified WHI analyses, synthesized by Manson in 2013 and again in 2024, found lower absolute adverse-event rates in women aged 50 to 59 or within about ten years of menopause than in older initiators, while still not supporting hormones as heart-disease prevention. The Menopause Society 2022 statement describes a more favorable benefit-risk balance for most healthy symptomatic women younger than 60 and within ten years of onset, and a less favorable balance after that window because of higher absolute risks of coronary disease, stroke, clots, and dementia. Age bands are group findings. They do not replace an individual history.
Review how long to continue with a clinician over time. Some clinicians stop systemic hormones at five years; some continue while bothersome symptoms persist. The 2022 Menopause Society statement says longer duration should be for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation. It does not set one mandatory stop date for every user. Manson’s WHI practice review still rejects using the same medicines as lifelong chronic-disease prevention. Monica Christmas, in public Menopause Society education, emphasizes matching the regimen to the person in front of you rather than to a slogan. The live disagreement is duration and purpose, not whether symptoms can be treated. Revisit the reason you started, current symptoms, and current risks instead of treating a round anniversary as a medical law.
Prefer regulated hormone products over custom compounded mixes. Compounded bioidentical hormone therapy is a pharmacist-mixed recipe promoted as more natural or more precise than approved products. The Endocrine Society’s position is that little or no scientific evidence shows these custom mixes are safer or more effective than FDA-approved hormone therapies, and that dose and purity can vary. A 2020 National Academies review reached a similar public-health concern: high-quality trials are lacking and oversight is limited. The Menopause Society has long warned that salivary hormone tests do not provide a useful dosing recipe in midlife because levels swing through the day. Approved estradiol and micronized progesterone are chemically identical to ovarian hormones when that is the molecule; the compounding debate is about the untested mix and the marketing, not the word bioidentical. Rare compounding for a documented allergy or shortage is a clinician-pharmacy decision, not a wellness upgrade.
Keep exercise for muscle and bone, not as a proven hot-flash cure. Public advice often says that lifting or yoga will shut off heat. The 2023 nonhormone statement reviewed that literature and did not recommend exercise, yoga, cooling tricks, or trigger-avoidance lists as vasomotor treatment. That is a statement about hot flashes as the outcome, not a claim that movement is useless. WHO activity guidance and LIFTMOR still support strength and impact work for muscle, function, and bone in the right setting. Kohrt’s menopause-exercise research likewise concerns body composition and musculoskeletal aging. A walk or a lift session can still be a good week for other reasons. It should not be sold as a substitute for vasomotor care that the field actually recommends.

talk Notes

Check how long heat actually lasts for you. A common saying is that hot flashes last a year or two and then vanish. Avis’s SWAN analysis found a median of more than seven years of frequent symptoms, and longer still for people who were premenopausal or early perimenopausal when frequent heat began. NIA public guidance also describes a wide two-to-eight-year symptom window, with large individual and group differences. Use your own calendar rather than a short folklore timer. If heat is still bothersome, that is a reason to talk with a clinician, not a reason to decide you are imagining it.
Use symptoms and history, not a saliva dosing recipe. Some clinics sell a spit panel that supposedly reveals the exact cream or capsule you need. The Menopause Society and Endocrine Society caution that midlife hormone levels vary by day and hour, and that custom mixes built from those numbers have not been shown to be safer or better than tested products. Jen Gunter's public teaching makes the same practical point: a fluctuating lab is a poor thermostat. Bring symptoms, history, and goals to a clinician. Do not treat a mail-order hormone map as a prescription.
Ask for named nonhormone options instead of herbal blends. Black cohosh, soy extracts, and mixed menopause-support bottles are widely sold as gentle hormone alternatives. The 2023 nonhormone statement does not recommend supplements or herbal remedies as vasomotor treatment, based on mixed or insufficient evidence. A bottle can still cause side effects or mix badly with other medicines. If you want a nonhormone option, the field has named therapies with trial support. Ask a clinician or pharmacist before adding a blend, and do not delay evaluation of heavy bleeding, early period stop, or crushing sleep loss while waiting on a supplement.
Choose hormone therapy from your history, not from a slogan. One internet camp treats hormone therapy as mandatory anti-aging. Another treats the 2002 WHI headline as a lifetime ban. Neither is the current named-source position. WHI did not support hormones for chronic-disease prevention in the enrolled population. The Menopause Society and Manson's later reviews still treat hormones as the most effective option for bothersome vasomotor symptoms in many healthy people who start nearer menopause and have no contraindication. Pauline Maki's cognition work is one reason late-life initiation is not treated as the same decision as early-symptom care. The useful move is a personal benefit-risk talk, not a slogan.

how People Run It

Bring one persistent-symptom picture to a clinician. Write four short lines you can actually use in a visit: how cycles have changed, how often heat or night sweats interrupt a day or a night, how sleep is going, and what you want help with first. NIA and NICE both start with that story in midlife rather than with a single lab. Faubion’s public Menopause Society teaching is built around matching treatment to bothersome symptoms and history, not around a universal hormone rule. This is an ordinary preparation step, not a diagnosis and not a request that you start or stop a medicine from a page.
Track cycle changes and heat for a few weeks. Note dates of bleeding, a rough count of daytime flashes and night sweats, and whether sleep broke. STRAW+10 uses persistent cycle-length change and gaps of sixty days as staging clues; Avis counted frequent vasomotor symptoms across years. A brief diary is a translation of those research tools into a visit aid. It does not diagnose you. If bleeding is suddenly very heavy, stacked close together, or returns after a full year without a period, skip the experiment and seek care.
Ask about CBT-I if sleep stays hard. If you have enough time in bed and still cannot sleep, or you wake and cannot return, ask a clinician or sleep program about cognitive behavioral therapy for insomnia. McCurry’s trial used six telephone sessions and improved insomnia scores in women who also had hot flashes. Joffe’s work is a reminder to mention night sweats and mood in the same conversation so the helper can see the whole night. This is a request for structured care, not a demand that you force sleep with more bedtime rules.
Ask about supervised strength and whether bone screening is due. If you already lift, keep the work and ask whether supervision, load, or screening needs a look. If you do not, ask a clinician what kind of strength work is reasonable and whether a DXA conversation fits your age and risk. USPSTF sets population screening ages; LIFTMOR tested a specific supervised high-intensity program in screened women with low bone mass. Neither source is a garage max-out plan. Stop and get assessed for sudden severe pain, a fall with injury, or warning symptoms during exercise.

how People Keep It

Use the stage name that matches the history. Perimenopause covers changing cycles and, in STRAW+10, continues through the twelve months after the final period. Menopause is recognized at the end of that interval when no other cause explains the absence of bleeding. Symptoms can continue afterward, so the anniversary does not promise that hot flashes or sleep disruption end. Hormonal treatments and surgery can change how a clinician establishes the stage.
Keep hormone therapy as a shared decision. The Menopause Society describes a generally favorable balance for many healthy symptomatic women who start under 60 and within ten years of onset, and a less favorable balance later. Manson’s WHI reviews still reject using the same medicines to prevent heart disease. Christmas’s society education stresses matching regimen to the person. Your history, preferences, and contraindications belong in that talk.
Review nonhormone options using current safety information. The Menopause Society’s 2023 statement remains useful for understanding options such as menopause-specific CBT and selected medicines, but it predates later regulatory changes. The FDA added a boxed liver-injury warning to fezolinetant in December 2024, with liver testing before and during treatment. It also approved elinzanetant, sold as LYNKUET, in October 2025 for moderate-to-severe hot flashes related to menopause. These dates do not rank treatments. Ask a prescriber about current indications, interactions and monitoring for the particular option being considered.
Keep strength work as health work. Kohrt and Beck study loading, estrogen, and bone as midlife physiology, not as a contest. WHO’s two-or-more days of muscle-strengthening activity is a population floor. LIFTMOR’s benefit appeared under supervision in a screened group. Do not copy a twenty-year-old’s program, and do not treat sore as a score. Muscle and bone are reasons to keep a repeatable session. They are not proof that heat will stop.
Keep a clinician in the loop for persistent symptoms. NIA tells people who are concerned by menopausal symptoms to talk with a doctor about lifestyle changes or medicines that might help. Recheck if symptoms worsen, if bleeding pattern changes, or if a medicine is not doing the job you hoped. A later appointment is part of ordinary care. It is not evidence that you failed the first plan.

claims Notes

Name menopause after twelve months without a period. Claim: “Menopause means periods have stopped for twelve months” — established. Twelve months without a period is the usual retrospective marker of natural menopause when another cause or hormonal treatment does not explain the absence of bleeding. STRAW+10 includes those twelve months within perimenopause. Younger age, surgery or medication-masked cycles can require a different clinical assessment.
Plan for heat that can last years. Claim: “Frequent hot flashes usually last only a year or two” — not what the research found. Avis found a median 7.4 years of frequent vasomotor symptoms in SWAN, with longer courses when frequent heat began before the final period. Two years is folklore, not the cohort result. Duration still varies widely, so use your own pattern and a clinician if the heat is bothersome.
Decide hormone therapy with a clinician, not a slogan. Claim: “Every woman in menopause should take hormone therapy” — not what the research found. The Menopause Society calls hormone therapy the most effective vasomotor treatment and a bone-protecting option in appropriate users. Manson’s WHI reviews still reject using it as chronic-disease prevention, and many people have contraindications or do not want it. Shared decision is the field position, not a mandate.
Keep hormones available as one option, not a ban. Claim: “The WHI proved that no one should ever take hormones” — not what the research found. The 2002 WHI combined-hormone trial answered a prevention question in a mostly older cohort and found overall risks exceeded benefits for that use. Later age-stratified analyses and the 2022 society statement still support treating bothersome vasomotor symptoms in many healthy people who start nearer menopause. A headline ban is not the current reading.
Keep exercise for muscle and bone, not as a hot-flash guarantee. Claim: “Exercise is a proven treatment for hot flashes” — not what the research found. The 2023 nonhormone statement does not recommend exercise or yoga as vasomotor treatment. Strength and activity still matter for muscle, function, and bone. Those are different jobs from shutting off heat.
Prefer tested hormone products over custom compounded mixes. Claim: “Custom compounded bioidentical hormones are safer than approved products” — not what the research found. The Endocrine Society and a 2020 National Academies review found a lack of high-quality evidence that custom compounded mixes are safer or more effective, and warned about variable dose and purity. Saliva tests are not a useful midlife dosing recipe. Approved products can already include body-identical estradiol and progesterone when that molecule is chosen.
Use structured insomnia care when nights stay broken. Claim: “CBT-I can improve insomnia during the menopause transition” — established. McCurry’s MsFLASH randomized trial found larger, lasting insomnia-score improvements with telephone CBT-I than with menopause education in peri- and postmenopausal women who also had hot flashes. Joffe’s work supports treating sleep as its own problem alongside vasomotor symptoms. CBT-I is structured care, not a guarantee, and breathing pauses still need clinical evaluation.

deep Dive

Use STRAW stages as a map, not a self-diagnosis. STRAW+10, led by Harlow, divides reproductive aging around the final menstrual period. Early transition means a persistent seven-day or greater difference in consecutive cycle lengths. Late transition means a gap of sixty days or more, often lasting one to three years. The twelve months after the last period close ordinary perimenopause; later postmenopause continues after hormones stabilize. The system was built so studies of midlife women could be compared, and it applies across age, ethnicity, body size, and lifestyle in the workshop’s judgment. Hormonal contraception, hysterectomy, and periods that stop before 40 need a different clinical approach. Use the map to describe what is happening. Do not treat it as a lab you can run on yourself.
Read the WHI with its original prevention question and the later age split. Rossouw’s 2002 estrogen-plus-progestin report stopped the combined trial early because overall risks exceeded benefits for chronic-disease prevention in a cohort whose mean age was about 63. Coronary events, stroke, pulmonary embolism, and invasive breast cancer were higher on the global index, while hip fracture and colorectal cancer were lower; all-cause mortality was not increased during the trial. Manson’s 2013 thirteen-year overview and 2024 practice review keep that prevention answer and add the age split: absolute harms were smaller in the 50-to-59 group, and hormones remain a vasomotor treatment option in early menopause without contraindications. Carolyn Crandall, a WHI investigator and NAMS panelist, helps keep bone and breast findings attached to the regimen actually studied. The reanalysis refined who faces which absolute risk. It did not convert the trial into a universal hormone mandate.
Distinguish estrogen-alone from combined therapy breast findings. In WHI, women with a uterus received oral conjugated estrogen plus medroxyprogesterone acetate; women with a hysterectomy received estrogen alone. During combined-therapy intervention, invasive breast cancer was higher than placebo. In the estrogen-alone trial, breast-cancer incidence was not increased and, with longer follow-up, was lower than placebo in Manson’s 2013 cumulative analysis. Those are different regimens, not proof that “estrogen is safe” or “hormones cause cancer” as a single sentence. A person with a uterus who uses systemic estrogen still needs endometrial protection with a progestogen, which is a separate, well-established gynecologic rule in the 2022 position statement. Breast-risk talk belongs with the actual product, duration, and personal history. It is not settled by a headline from one arm.
Ask about skin versus pill when clotting risk is part of the talk. The 2022 Menopause Society statement notes that transdermal routes and lower doses may decrease risk of venous thromboembolism and stroke compared with higher-dose oral regimens. That is a comparative safety signal from observational and mechanistic work, not a randomized promise that a patch erases clot risk. Oral combined therapy in WHI increased pulmonary embolism. Shufelt’s women’s-heart research is one reason cardiology and menopause care now ask about route, dose, and baseline clot or stroke history. If a clinician is considering hormones and you have migraine with aura, prior clots, or other vascular history, that history belongs in the first sentence, not as an afterthought. Route is a shared-decision detail. It is not a DIY swap.
Use CBT to reduce how much heat bothers daily life. Myra Hunter developed brief cognitive-behavioral therapy for hot flushes and night sweats and tested group and self-help versions in women with natural menopause and in women after breast-cancer treatment. Those trials, now reflected in NICE and in the 2023 nonhormone statement, found substantial reductions in how much heat interfered with life, with smaller or mixed effects on physiologic flash counts depending on the group. The method works on attention, appraisal, and behavioral responses to an episode, not by adding estrogen. Carpenter’s symptom-science work likewise separates frequency from bother. If the goal is to get through a meeting or a night with less distress, CBT is a named tool. It is not a claim that the nervous system has invented the flash.
Separate night sweats from an independent insomnia pattern. Joffe’s reviews describe two overlapping problems: awakenings tied to vasomotor events, and sleep disturbance that remains after those events and mood are considered. McCurry’s CBT-I group slept better and reported less hot-flash interference without a change in daily flash frequency versus education. That pattern is why treating insomnia can help a menopause-related night even when heat continues. It is also why a wearable score is not a diagnosis. If the main complaint is heat, vasomotor treatment may be the first lever. If the main complaint is not being able to sleep despite time in bed, ask for insomnia care. Many people need both conversations. Neither is a moral failure.
Use supervised heavy lifting as a researched bone option. LIFTMOR randomized postmenopausal women with osteopenia or osteoporosis, after screening out selected medical problems, to eight months of twice-weekly, thirty-minute, supervised high-intensity resistance and impact training or a home low-intensity program. The lifting group used five sets of five repetitions above 85 percent of one-repetition maximum. Lumbar-spine density and functional tests improved more than in the control group; one minor back spasm was the reported adverse event under that supervision. Beck’s group designed the protocol because ordinary walking often does not load bone enough to change density. This is evidence that heavy, coached loading can be studied safely in screened women. It is not permission to load a bar to failure alone in a garage, and it is not a fracture-treatment plan after a break.
Bring an early change in ovarian function to a clinician. Premature ovarian insufficiency means loss of normal ovarian activity before age 40; early menopause usually refers to ages 40–44. The international POI guideline explains that ovarian activity can still occur in nonsurgical POI, so the label is not a guarantee of infertility. Assessment considers the cycle history, tests and possible causes rather than waiting for the usual menopause anniversary. Bone and cardiovascular health, fertility goals and symptoms all enter the care discussion. Hormone treatment in POI may serve health needs through the usual age of menopause, subject to individual contraindications. That is a different decision from starting treatment later in life.

related

sleep
fitness
anxiety

watch For Long

Good to know. This is a reading companion, not a diagnosis, hormone prescription, or clinic visit. Persistent or bothersome heat, night sweats, broken sleep, early period stop, or worry about bone belong with a qualified clinician who can take a history and tailor care. After more than a year without a period, new bleeding or spotting needs prompt medical review. Periods that stop before 45, very heavy or closely stacked bleeding, and sudden severe symptoms also need a person, not a page. Do not start, stop, or change hormone therapy, other medicines, or a training plan from this text. Chest pain, fainting, one-sided weakness, or sudden breathlessness need emergency care. This page does not treat one body or promise an outcome.
Not advice. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

sources

Stephanie Faubion. Mayo Clinic internist, Center for Women’s Health director, and medical director of The Menopause Society. She led the 2022 hormone-therapy position statement. Relevant work: society guidance on hot flashes, night sweats, and treatment timing.
JoAnn Manson. Harvard and Brigham endocrinologist-epidemiologist and longtime WHI principal investigator. Her 2013 and 2024 reviews are the named re-reading of hormone therapy after the original prevention trial. They do not create a personal prescription.
Nanette Santoro. University of Colorado reproductive endocrinologist, SWAN investigator, and NAMS 2022 panelist. She helps explain cycle and hormone swing during the transition. Clinic care remains individual.
Rebecca Thurston. University of Pittsburgh psychologist and vasomotor-symptom researcher, past president of The Menopause Society. She keeps heat attached to sleep, mood, and later health research without turning a flash count into a diagnosis.
Hadine Joffe. Harvard psychiatrist and midlife sleep researcher, past NAMS president. Her work separates night sweats from insomnia that needs its own care. It is not a home sleep protocol.
Pauline Maki. University of Illinois Chicago psychologist studying menopause, mood, and cognition. She contributed to STRAW+10 and NAMS statements. Cognitive findings in older WHI participants are not a memory test for a 52-year-old.
Sioban Harlow. University of Michigan reproductive epidemiologist who led STRAW+10 and the Michigan SWAN site. Staging is a research and clinical map. She is now emeritus and is not a treating clinician for a visitor.
Chrisandra Shufelt. Mayo Clinic women’s-health internist, past Menopause Society president, and lead of the 2023 nonhormone statement. She connects hormones, heart, and vasomotor options. Cardiology decisions still need a personal history.
Carolyn Crandall. UCLA internist, WHI investigator, and coauthor of the 2023 JAMA menopausal-symptom review. She keeps bone, breast, and symptom treatment attached to the evidence. Reviews are not bedside orders.
Wendy Kohrt. University of Colorado distinguished professor studying exercise, estrogen, and midlife body composition. She supports taking physical activity seriously in the transition. Her studies are not a gym template.
Belinda Beck. Griffith University exercise physiologist and LIFTMOR investigator. She showed supervised high-intensity lifting can be studied in women with low bone mass. The trial is not unsupervised heavy lifting.
Myra Hunter. King’s College London emeritus clinical health psychologist who developed CBT for hot flushes and night sweats. Her trials support reducing bother. They do not replace medical evaluation.
Jen Gunter. Kaiser Permanente obstetrician-gynecologist and public author of menopause explainers. She helps people reject saliva-test dosing and supplement promises. Books and columns are teaching, not new trials.
Monica Christmas. University of Chicago gynecologist, menopause-program director, and associate medical director of The Menopause Society. She translates society guidance into ordinary care conversations. A society role is not independent trial evidence.
Nancy Avis. Wake Forest professor and SWAN investigator who measured how long frequent vasomotor symptoms last. The median is a group finding. It cannot date one person’s last flash.

source Links

STRAW-2012

name

Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–395.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/22343510/
label
PMC
href
https://pmc.ncbi.nlm.nih.gov/articles/PMC3580996/

NIA-MENOPAUSE-2024

name

National Institute on Aging. What Is Menopause? Content reviewed October 16, 2024.

kind

evidence

links

label
Official page
href
https://www.nia.nih.gov/health/menopause/what-menopause

NICE-NG23

name

National Institute for Health and Care Excellence. Menopause: identification and management (NG23) and CKS diagnosis summary.

kind

evidence

links

label
NICE quality statement
href
https://www.nice.org.uk/guidance/qs143/chapter/quality-statement-1-diagnosing-perimenopause-and-menopause
label
CKS diagnosis
href
https://cks.nice.org.uk/topics/menopause/diagnosis/diagnosis-of-menopause-perimenopause/

NAMS-HT-2022

name

The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/35797481/
label
Journal
href
https://journals.lww.com/menopausejournal/fulltext/2022/07000/the_2022_hormone_therapy_position_statement_of_the.4.aspx
label
The Menopause Society
href
https://menopause.org/

NAMS-NONHORMONE-2023

name

The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590.

kind

evidence

links

label
DOI
href
https://doi.org/10.1097/GME.0000000000002200
label
Journal
href
https://journals.lww.com/menopausejournal/fulltext/2023/06000/the_2023_nonhormone_therapy_position_statement_of.4.aspx

WHI-2002

name

Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/12117397/
label
JAMA
href
https://jamanetwork.com/journals/jama/fullarticle/195120

WHI-MANSON-2013

name

Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/24084921/

WHI-MANSON-2024

name

Manson JE, Crandall CJ, Rossouw JE, et al. The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748–1760.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/38691368/
label
JAMA
href
https://jamanetwork.com/journals/jama/fullarticle/2818206

AVIS-VMS-2015

name

Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/25686030/
label
PMC
href
https://pmc.ncbi.nlm.nih.gov/articles/PMC4433164/

MCCURRY-MSFLASH-2016

name

McCurry SM, Guthrie KA, Morin CM, et al. Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial. JAMA Intern Med. 2016;176(7):913–920.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/27213646/
label
PMC
href
https://pmc.ncbi.nlm.nih.gov/articles/PMC4935624/

CRANDALL-JAMA-2023

name

Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405–420.

kind

evidence

links

label
DOI
href
https://doi.org/10.1001/jama.2022.24140
label
JAMA
href
https://jamanetwork.com/journals/jama/fullarticle/2801054

LIFTMOR-2018

name

Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial. J Bone Miner Res. 2018;33(2):211–220.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/28975661/
label
DOI
href
https://doi.org/10.1002/jbmr.3284

USPSTF-BONE-2025

name

U.S. Preventive Services Task Force. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2025;333(6):498–508.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/39808425/
label
USPSTF clinician summary
href
https://www.uspreventiveservicestaskforce.org/uspstf/document/ClinicalSummaryFinal/osteoporosis-screening

WHO-PA-2020

name

World Health Organization. WHO Guidelines on Physical Activity and Sedentary Behaviour. 2020.

kind

evidence

links

label
Guideline
href
https://www.who.int/publications/i/item/9789240015128

NASEM-CBHT-2020

name

National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington, DC: National Academies Press; 2020.

kind

evidence

links

label
NCBI Bookshelf
href
https://www.ncbi.nlm.nih.gov/books/NBK562884/
label
FDA summary of the study
href
https://www.fda.gov/drugs/human-drug-compounding/national-academies-science-engineering-and-medicine-nasem-study-clinical-utility-treating-patients

ENDO-CBHT-2019

name

Endocrine Society. Compounded Bioidentical Hormone Therapy. Position statement reissued October 2, 2019.

kind

evidence

links

label
Official statement
href
https://www.endocrine.org/advocacy/position-statements/compounded-bioidentical-hormone-therapy

FAUBION-MENOPAUSE-2026

name

Stephanie Faubion

kind

professional

links

label
Mayo biography
href
https://www.mayoclinic.org/biographies/faubion-stephanie-s-m-d-m-b-a/bio-20054845
label
Mayo research profile
href
https://www.mayo.edu/research/faculty/faubion-stephanie-s-m-d-m-b-a/bio-20199366

MANSON-MENOPAUSE-2026

name

JoAnn Manson

kind

professional

links

label
Division profile
href
https://prevmed.bwh.harvard.edu/joann-e-manson-md-dph/
label
Harvard Health biography
href
https://www.health.harvard.edu/authors/joann-manson-md-drph

SANTORO-MENOPAUSE-2026

name

Nanette Santoro

kind

professional

links

label
CU Anschutz faculty
href
https://medschool.cuanschutz.edu/ob-gyn/divisions/division-of-reproductive-sciences/our-faculty/nanette-santoro-md
label
Endocrine Society profile
href
https://www.endocrine.org/our-community/profiles/santoro-nanette

THURSTON-MENOPAUSE-2026

name

Rebecca Thurston

kind

professional

links

label
Pitt psychiatry profile
href
https://www.psychiatry.pitt.edu/about-us/our-people/faculty/rebecca-c-thurston-phd
label
Lab about page
href
https://www.thurstonlab.pitt.edu/about-us/

JOFFE-MENOPAUSE-2026

name

Hadine Joffe

kind

professional

links

label
BWH Connors Center
href
https://www.brighamandwomens.org/womens-health/connors-center/connors-center-for-womens-health
label
UChicago biographical note
href
https://obgyn.uchicago.edu/admin/person/hadine-joffe

MAKI-MENOPAUSE-2026

name

Pauline Maki

kind

professional

links

label
UIC psychology profile
href
https://psch.uic.edu/profiles/maki-pauline/
label
UIC medicine profile
href
https://chicago.medicine.uic.edu/profiles/maki-pauline/

HARLOW-MENOPAUSE-2026

name

Sioban Harlow

kind

professional

links

label
U-M SPH profile
href
https://sph.umich.edu/faculty-profiles/harlow-sioban.html

SHUFELT-MENOPAUSE-2026

name

Chrisandra Shufelt

kind

professional

links

label
Mayo biography
href
https://www.mayoclinic.org/biographies/shufelt-chrisandra-l-m-d/bio-20534816
label
Mayo research profile
href
https://www.mayo.edu/research/faculty/shufelt-chrisandra-l-m-d/bio-20542101

CRANDALL-MENOPAUSE-2026

name

Carolyn Crandall

kind

professional

links

label
UCLA Health / JCCC profile
href
https://www.uclahealth.org/cancer/members/carolyn-crandall

KOHRT-MENOPAUSE-2026

name

Wendy Kohrt

kind

professional

links

label
Ludeman Center faculty
href
https://medschool.cuanschutz.edu/center-for-womens-health-research/about-us/faculty-leadership/wendy-kohrt

BECK-MENOPAUSE-2026

name

Belinda Beck

kind

professional

links

label
Griffith expert profile
href
https://experts.griffith.edu.au/18574-belinda-beck

HUNTER-MENOPAUSE-2026

name

Myra Hunter

kind

professional

links

label
KCL profile
href
https://www.kcl.ac.uk/people/myra-hunter

GUNTER-MENOPAUSE-2026

name

Jen Gunter

kind

professional

links

label
Kaiser physician profile
href
https://mydoctor.kaiserpermanente.org/ncal/doctor/jennifergunter

CHRISTMAS-MENOPAUSE-2026

name

Monica Christmas

kind

professional

links

label
UChicago Medicine profile
href
https://www.uchicagomedicine.org/find-a-physician/physician/monica-christmas
label
Society appointment
href
https://menopause.org/press-releases/the-menopause-society-appoints-dr-monica-christmas-as-associate-medical-director

AVIS-MENOPAUSE-2026

name

Nancy Avis

kind

professional

links

label
Wake Forest Profiles RNS
href
https://profiles.wakehealth.edu/display/person/navis

MENOPAUSE-STAGES-WAVE

name

Canadian Menopause Society: Definition and Stages. Source

kind

evidence

links

label
Source
href
https://www.canadianmenopausesociety.org/professionals/menopause-hub/definition/

FDA-FEZO-2024

name

VEOZAH prescribing information, December 2024 boxed warning. Source

kind

evidence

links

label
Source
href
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf

FDA-LYNKUET-2025

name

FDA Drug Trials Snapshot: LYNKUET. Source

kind

evidence

links

label
Source
href
https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lynkuet

POI-GUIDELINE-WAVE

name

ESHRE, ASRM, CRE-WHiRL and IMS: Evidence-based guideline on premature ovarian insufficiency. Source

kind

evidence

links

label
Source
href
https://www.asrm.org/practice-guidance/practice-committee-documents/evidence-based-guideline-premature-ovarian-insufficiency--2024/

source Claims

situations.stage

STRAW-2012
NIA-MENOPAUSE-2024
NICE-NG23
HARLOW-MENOPAUSE-2026
SANTORO-MENOPAUSE-2026
MENOPAUSE-STAGES-WAVE

situations.heat

AVIS-VMS-2015
AVIS-MENOPAUSE-2026
THURSTON-MENOPAUSE-2026

situations.sleep

MCCURRY-MSFLASH-2016
JOFFE-MENOPAUSE-2026

situations.bone

NAMS-HT-2022
LIFTMOR-2018
USPSTF-BONE-2025
BECK-MENOPAUSE-2026
KOHRT-MENOPAUSE-2026

split.established.0

NIA-MENOPAUSE-2024
STRAW-2012
NICE-NG23
SANTORO-MENOPAUSE-2026

split.established.1

AVIS-VMS-2015
CRANDALL-JAMA-2023
THURSTON-MENOPAUSE-2026
AVIS-MENOPAUSE-2026

split.established.2

NAMS-HT-2022
CRANDALL-JAMA-2023
WHI-MANSON-2024
FAUBION-MENOPAUSE-2026
MANSON-MENOPAUSE-2026

split.established.3

NAMS-NONHORMONE-2023
SHUFELT-MENOPAUSE-2026
HUNTER-MENOPAUSE-2026

split.established.4

MCCURRY-MSFLASH-2016
JOFFE-MENOPAUSE-2026

split.established.5

WHO-PA-2020
USPSTF-BONE-2025
LIFTMOR-2018
KOHRT-MENOPAUSE-2026

split.disputed.0

WHI-2002
WHI-MANSON-2013
WHI-MANSON-2024
NAMS-HT-2022
MANSON-MENOPAUSE-2026

split.disputed.1

NAMS-HT-2022
WHI-MANSON-2024
CHRISTMAS-MENOPAUSE-2026

split.disputed.2

NASEM-CBHT-2020
ENDO-CBHT-2019
NAMS-HT-2022

split.disputed.3

NAMS-NONHORMONE-2023
WHO-PA-2020
LIFTMOR-2018
KOHRT-MENOPAUSE-2026

split.talk.0

AVIS-VMS-2015
NIA-MENOPAUSE-2024

split.talk.1

ENDO-CBHT-2019
NAMS-HT-2022
GUNTER-MENOPAUSE-2026

split.talk.2

NAMS-NONHORMONE-2023

split.talk.3

WHI-2002
NAMS-HT-2022
WHI-MANSON-2024
MAKI-MENOPAUSE-2026

move

NIA-MENOPAUSE-2024
NICE-NG23
FAUBION-MENOPAUSE-2026

try.0

STRAW-2012
AVIS-VMS-2015
NIA-MENOPAUSE-2024

try.1

MCCURRY-MSFLASH-2016
JOFFE-MENOPAUSE-2026

try.2

USPSTF-BONE-2025
LIFTMOR-2018
WHO-PA-2020

keep.0

STRAW-2012
NIA-MENOPAUSE-2024
HARLOW-MENOPAUSE-2026
MENOPAUSE-STAGES-WAVE
AVIS-VMS-2015

keep.1

NAMS-HT-2022
WHI-MANSON-2024
CHRISTMAS-MENOPAUSE-2026

keep.2

NAMS-NONHORMONE-2023
HUNTER-MENOPAUSE-2026
FDA-FEZO-2024
FDA-LYNKUET-2025

keep.3

KOHRT-MENOPAUSE-2026
BECK-MENOPAUSE-2026
WHO-PA-2020

keep.4

NIA-MENOPAUSE-2024

deep.0

STRAW-2012
HARLOW-MENOPAUSE-2026

deep.1

WHI-2002
WHI-MANSON-2013
WHI-MANSON-2024
CRANDALL-MENOPAUSE-2026

deep.2

WHI-MANSON-2013
NAMS-HT-2022
CRANDALL-JAMA-2023

deep.3

NAMS-HT-2022
WHI-2002
SHUFELT-MENOPAUSE-2026

deep.4

NAMS-NONHORMONE-2023
HUNTER-MENOPAUSE-2026

deep.5

MCCURRY-MSFLASH-2016
JOFFE-MENOPAUSE-2026

deep.6

LIFTMOR-2018
BECK-MENOPAUSE-2026

deep.7

NAMS-HT-2022
NIA-MENOPAUSE-2024
SANTORO-MENOPAUSE-2026
POI-GUIDELINE-WAVE

claims.0

NIA-MENOPAUSE-2024
STRAW-2012
NICE-NG23
MENOPAUSE-STAGES-WAVE

claims.1

AVIS-VMS-2015

claims.2

NAMS-HT-2022
WHI-MANSON-2024

claims.3

WHI-2002
WHI-MANSON-2024
NAMS-HT-2022

claims.4

NAMS-NONHORMONE-2023

claims.5

NASEM-CBHT-2020
ENDO-CBHT-2019

claims.6

MCCURRY-MSFLASH-2016
JOFFE-MENOPAUSE-2026

watch For

NIA-MENOPAUSE-2024
NICE-NG23
NAMS-HT-2022

source Situation Keys

situations.stage
situations.heat
situations.sleep
situations.bone

professional Source Ids

FAUBION-MENOPAUSE-2026
MANSON-MENOPAUSE-2026
SANTORO-MENOPAUSE-2026
THURSTON-MENOPAUSE-2026
JOFFE-MENOPAUSE-2026
MAKI-MENOPAUSE-2026
HARLOW-MENOPAUSE-2026
SHUFELT-MENOPAUSE-2026
CRANDALL-MENOPAUSE-2026
KOHRT-MENOPAUSE-2026
BECK-MENOPAUSE-2026
HUNTER-MENOPAUSE-2026
GUNTER-MENOPAUSE-2026
CHRISTMAS-MENOPAUSE-2026
AVIS-MENOPAUSE-2026

house Pointers

href
/self/
label
STUDself. Community experiences with sleep. For discussions of lifting after 40, see STUDfit.

positive Guidance

status: DONE
reviewed At: 2026-09-12
professional Count: 15
scope: content-and-positive-titles-only

learn Article

article

format version

presentation

complete-card

overview

sections

id
understanding-the-transition
role
explanation
title
What changes around the last period
intro
The stage name describes ovarian aging. It does not tell you how much help you need or when symptoms will end.
items
- label
  Understand menopause as a life stage with a changing hormone pattern
  text
  Menopause is the point at which periods have permanently ended because the ovaries have lost their usual follicular function. A follicle is the small structure in an ovary that contains a developing egg. During perimenopause, the years around that point, ovarian activity becomes less predictable; estrogen can fluctuate before settling at a lower level. This helps explain why changing cycles, sudden heat and disrupted nights can occur together. WHO describes substantial variation: some women have few symptoms, while others have symptoms that interfere with daily life. A normal life stage can still deserve treatment. Its significance is how it affects you, rather than whether you match someone else's symptom list. Mayo Clinic gives a U.S. average menopause age of 51, while estimates differ slightly across sources; an average age is not a personal deadline.
  source ids
  who-menopause
  endo-menopause
  mayo-menopause
- label
  Use the calendar to describe the stage, with room for exceptions
  text
  For natural menopause, the usual marker is twelve consecutive months without a period when another cause does not explain the absence. It is retrospective: you recognize the final menstrual period after time has passed. Siobán Harlow and the STRAW+10 workshop use persistent differences of at least seven days between consecutive cycle lengths to mark early transition, and a gap of at least sixty days to mark late transition. That late stage commonly lasts one to three years; their definition of perimenopause extends through the first twelve months after the final period. The workshop intended a common framework across age, ethnicity, body size and lifestyle, while recognizing situations where bleeding criteria are harder to use. These are staging clues, not instructions to diagnose yourself. Hormonal contraception can mask bleeding. A hysterectomy removes the uterus, so the period calendar is lost even if the ovaries remain; removal of both ovaries is a different event. A clinician interprets symptoms, surgery and medication history together.
  source ids
  straw-2012
  cms-stages
- label
  Let a clinical history answer the routine midlife testing question
  text
  FSH, or follicle-stimulating hormone, is a signal involved in ovarian function. Its level can fluctuate during the transition, making one measurement a poor summary of the preceding months. NICE recommends identifying typical perimenopause or menopause clinically in otherwise healthy people aged 45 or over with relevant symptoms, rather than routinely ordering hormone or ovarian-reserve tests. That recommendation does not mean every test is useless or every new symptom is menopause. Younger age, an unusual presentation or medication-masked cycles can change the assessment. The practical preparation is a history of bleeding, symptoms and medicines. Ask what question a proposed blood test would answer before treating its number as the final verdict.
  source ids
  nice-ng23
  endo-menopause
- label
  Seek assessment when periods stop before 45
  text
  Periods stopping unusually early need assessment rather than a wait for the ordinary twelve-month anniversary. The international ovarian-insufficiency guideline distinguishes premature ovarian insufficiency, or POI, before age 40 from early menopause at ages 40–44. POI means loss of normal ovarian activity, but nonsurgical POI can include intermittent activity and a chance of natural conception. It is not synonymous with an absolute infertility verdict. The care discussion includes causes, symptoms, bone and cardiovascular health, and fertility goals. Hormone treatment may address health needs until the usual menopause age even without troublesome heat, subject to the person's history. That differs from starting hormones much later for disease prevention. The guideline also acknowledges limited evidence for many POI-specific choices; an individualized assessment remains essential.
  source ids
  poi-guideline
  cms-stages
id
recognize-your-main-question
role
application
title
Which part is disrupting your life?
intro
These four situations help identify the question to bring to care. Several can be true at once.
items
- label
  Describe changing periods before trying to name the final one
  text
  You might be thinking, 'My periods are farther apart, but they still come—am I in menopause?' The answer is that changing cycles can fit perimenopause before menopause can be confirmed retrospectively. The Canadian Menopause Society describes the distinction through both bleeding patterns and symptoms, while NICE emphasizes the clinical story in typical midlife presentations. Write down when bleeding occurred, how it changed and whether you use hormonal medicines. Include surgery history if it applies. A symptom diary is a communication aid, not an obligation to collect a perfect year of data before asking for help. Very heavy, unusually frequent or new postmenopausal bleeding belongs in an assessment rather than being assumed to be another stage marker. Imagine someone brings a note saying 'probably menopause' but no description of what changed. A more useful account separates changing cycle dates, interrupted sleep and how symptoms affect daily life, alongside relevant medicines or surgery. Those details give the clinician questions to assess instead of a label to accept. A missing date can be marked uncertain; it need not delay seeking help. If a symptom improves while another persists, that is worth describing separately at follow-up. It does not mean the whole experience must have one cause or one treatment. This invented visit preparation illustrates the difference between describing a stage and investigating a symptom. It does not determine menopause from a diary, prescribe a test, or make unexpected bleeding something to watch indefinitely rather than bring to clinical attention.
  source ids
  cms-stages
  nice-ng23
  nhs-heavy-bleeding
- label
  Describe what heat interrupts, as well as how often it happens
  text
  You might be thinking, 'The heat is still interrupting meetings years later—shouldn't it be over?' A vasomotor symptom is a hot flash or night sweat: a sudden heat episode, often with flushing and sweating. The Menopause Society explains that episodes differ greatly in frequency and severity. For a visit, 'I lose my train of thought twice during most meetings' or 'I change bedding at night' can be as useful as a rough episode count. Those details describe interference, which is a meaningful treatment outcome. They help distinguish a tolerable symptom from a symptom worth treating. A new or unusual pattern of sweating still deserves clinical consideration; the word menopause should not explain away every possible cause.
  source ids
  society-hot-flashes
  avis-duration
- label
  Describe the whole night when sleep remains difficult
  text
  You might be thinking, 'I have time to sleep, but I keep waking and cannot get back to sleep.' Night sweats can be one cause of waking, while an insomnia pattern can persist alongside them. Hadine Joffe studies these overlapping problems, and Susan McCurry's trial tested structured insomnia care in women who also had hot flashes. Tell the clinician whether heat woke you, whether you were already awake, how long returning to sleep took and what happens during the day. Also mention loud snoring, gasping or witnessed breathing pauses. The National Heart, Lung, and Blood Institute identifies these as reasons to consider sleep apnea, which requires its own assessment. A wearable's reassuring sleep score does not replace that history.
  source ids
  mccurry-cbti
  p-joffe
  nhlbi-apnea
- label
  Ask about bone health and strength even without pain
  text
  You might be thinking, 'I feel fine, but do I need to change my lifting or get a bone scan?' Bone loss often gives no useful day-to-day warning before a fracture. USPSTF screening guidance uses age and fracture-risk factors rather than whether someone feels strong. Wendy Kohrt's work also distinguishes changes in muscle and body composition from symptoms such as hot flashes. Mention previous fractures, falls, medicines that affect bone and the activity you currently do. A bone-density discussion and a supervised exercise discussion serve different purposes: one helps assess risk, the other helps choose suitable loading. Neither assumes that every person needs a scan immediately or should begin heavy lifting from a generic page.
  source ids
  uspstf-bone
  p-kohrt
  liftmor-2018
id
heat-duration-and-meaning
role
findings
title
What hot-flash research actually measured
intro
Averages are useful for expectations. They cannot supply your personal stop date.
items
- label
  Allow for a course measured in years
  text
  Crandall and colleagues' clinical review estimates that roughly 50%–75% of women have vasomotor symptoms during the transition. Nancy Avis and colleagues analyzed 1,449 women with frequent hot flashes or night sweats in the Study of Women's Health Across the Nation, or SWAN. Frequent meant symptoms on at least six days in the preceding two weeks. The median total duration was 7.4 years; among 881 women whose final period was observed, symptoms persisted a median of 4.5 years after it. A median is the middle of the observed distribution, not a treatment deadline. Women reporting frequent symptoms before or early in the transition tended to have longer courses, and African American women had the longest median among the groups studied. These observations correct the idea of a universal one- or two-year limit. They do not predict one person's duration or establish an inherent biological explanation for every group difference.
  source ids
  avis-duration
  crandall-review
- label
  Measure relief in the outcome that matters to you
  text
  A therapy can reduce episode frequency, lessen severity, improve sleep or make heat less disruptive without doing all four equally. Myra Hunter's MENOS studies illustrate the distinction. King's College London's report describes two randomized trials: one in 96 women after breast-cancer treatment, and another in 140 otherwise healthy women with troublesome menopause symptoms. Group or guided self-help cognitive behavioral therapy improved how problematic participants rated hot flashes and night sweats, with benefits sustained through 26 weeks. The method helps with interpretations and responses to episodes; it does not imply that heat is imaginary. Research on flash counts and research on coping answer different questions. When reviewing a treatment, ask which outcome improved, compared with what, and in which group.
  source ids
  menos-trials
  p-hunter
id
options-for-bothersome-heat
role
findings
title
Which treatments have evidence for heat?
intro
Treatment choice depends on your goals, medical history, preferences, availability and the particular product.
items
- label
  Consider hormone therapy for troublesome symptoms
  text
  Systemic hormone therapy circulates through the body, commonly using estrogen with an additional protective medicine when needed. Carolyn Crandall, Jyothi Mehta and JoAnn Manson's 2023 clinical review describes systemic estrogen as reducing vasomotor-symptom frequency by roughly 75% on average in the reviewed research. A review estimate is not a promised result for one person. The Menopause Society's 2022 statement calls hormone therapy the most effective vasomotor treatment and records benefits for bone loss and fracture. It describes a generally favorable benefit-risk balance for appropriately selected symptomatic women younger than 60 or within ten years of menopause onset, without contraindications. That supports an informed option rather than a universal requirement. The reasons to consider it, and the reasons it may not suit you, belong in the same discussion.
  source ids
  crandall-review
  society-ht-2022
- label
  Ask which nonhormone option matches your goal and history
  text
  Nonhormone does not mean untested, and it does not mean free of side effects. Chrisandra Shufelt's 2023 Menopause Society panel recommended menopause-specific CBT, clinical hypnosis, selected SSRI/SNRI medicines, gabapentin and fezolinetant on its strongest evidence tier. SSRI and SNRI describe medicine classes that affect brain signaling; some are used for hot flashes as well as other conditions. The panel gave different evidence ratings to oxybutynin, weight loss and stellate ganglion block, an injection near nerves in the neck. Those options are not interchangeable, and the injection is a specialist procedure. A 2023 list also predates later approvals and safety changes. A prescriber can explain indication, interactions, monitoring and expected benefit for the option being considered; this is not a menu to combine yourself.
  source ids
  society-nonhormone-2023
  society-nonhormone-handout
  p-shufelt
- label
  Review safety requirements for medicines that target hot flashes
  text
  Fezolinetant, sold as VEOZAH, blocks a neurokinin-3 receptor involved in temperature regulation rather than supplying estrogen. The FDA added a boxed warning for rare serious liver injury in December 2024. Its safety communication describes liver bloodwork before treatment, monthly for the first three months, then at months six and nine, and instructions to stop the medicine and seek medical attention if liver-injury symptoms develop. Yellow skin or eyes, dark urine or new abdominal pain are examples to discuss promptly. Elinzanetant, sold as LYNKUET, blocks neurokinin-1 and -3 receptors; the FDA approved it on October 24, 2025 for moderate-to-severe menopausal heat. Its approval label also requires liver assessment and warns about drowsiness, daytime impairment, interactions and pregnancy. 'Nonhormonal' describes mechanism, not a safety guarantee.
  source ids
  fda-veozah-safety
  fda-veozah-label
  fda-lynkuet-snapshot
  fda-lynkuet-label
- label
  Read a new approval through the comparison it tested
  text
  The FDA's LYNKUET snapshot describes two main efficacy trials in postmenopausal women with at least fifty moderate-to-severe hot flashes per week. At twelve weeks, the drug groups averaged about 3.2 fewer daily episodes than placebo after adjustment for baseline and trial factors. Both drug and placebo groups improved, so the extra difference is more informative than the drug group's change alone. The trials were not a head-to-head comparison with hormone therapy or fezolinetant. The FDA's tables describe participants aged 40–65, leaving older adults outside that reported age range; some racial groups had too few participants for confident subgroup conclusions. Approval establishes a tested option for a defined use. It does not establish that this is the best treatment for every stage, age or medical history.
  source ids
  fda-lynkuet-snapshot
id
weigh-hormone-decisions
role
perspectives
title
Why hormone advice can sound contradictory
intro
Timing, formulation, route and duration are genuine decision questions. They should stay distinct from public slogans about mandatory treatment or a lifetime ban.
items
- label
  Read the WHI answer with the regimen and prevention question attached
  text
  The Women's Health Initiative's 2002 combined-hormone trial enrolled 16,608 postmenopausal women aged 50–79, with a mean age around 63. It compared a daily oral regimen of conjugated equine estrogen, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, with placebo. The trial stopped after an average 5.2 years because the overall prevention balance favored harm: more coronary events, stroke, pulmonary embolism and invasive breast cancer, alongside fewer hip fractures and colorectal cancers. All-cause mortality was not affected during that trial. Those findings matter. They are not a trial of every modern hormone product or of every younger person seeking symptom relief. JoAnn Manson's 2024 review preserves the conclusion against using hormones for broad chronic-disease prevention while allowing treatment for bothersome heat in suitable early-menopause candidates.
  source ids
  whi-2002
  whi-review-2024
- label
  Compare absolute risk as well as relative risk
  text
  A relative risk describes a proportional difference; absolute risk describes how many people experience an event. The same proportional increase can produce more additional events in an older group with a higher starting risk. Manson's thirteen-year WHI overview found lower absolute adverse-event rates in younger participants than in older participants, with important differences between regimens. The age analyses refine the conversation; they are not a separate trial proving that every modern regimen prevents disease when started early. The original combined trial reported about eight additional invasive breast cancers per 10,000 person-years with its regimen. That figure belongs to its population and follow-up, rather than becoming your own annual risk. Ask for the baseline risk, the additional events and the time horizon relevant to the proposed product.
  source ids
  whi-followup-2013
  whi-2002
- label
  Keep estrogen-alone and combined-therapy findings separate
  text
  WHI assigned women with a uterus to the combined estrogen/progestin trial and women with a prior hysterectomy to the estrogen-alone trial. Manson's 2013 cumulative analysis found higher invasive breast-cancer incidence with the combined regimen and lower incidence with the studied estrogen-alone regimen than with placebo. These are different trial populations and treatments, not permission to use estrogen alone when the uterus is present. Systemic estrogen can stimulate the endometrium, the uterine lining, so appropriate endometrial protection is needed, usually with a progestogen. A progestogen is a medicine with progesterone-like protective effects. The breast findings do not settle uterine safety. In a visit, identify the actual regimen and why its components are needed before comparing headline claims about 'hormones.'
  source ids
  whi-followup-2013
  society-ht-handout
  society-ht-patient
- label
  Discuss route as a risk detail, with honest uncertainty
  text
  Transdermal estrogen enters through the skin, such as from a patch or gel; oral estrogen is swallowed. The Menopause Society notes evidence suggesting lower clot risk with transdermal treatment, while also explaining the lack of large randomized head-to-head trials for major clinical outcomes. A possible comparative advantage is not proof that patches eliminate stroke, clot or breast-cancer risk. Prior clots, stroke, heart disease, liver disease, unexplained bleeding and estrogen-sensitive cancers can change whether systemic therapy is appropriate at all. Mention vascular history, migraine history, medicines and surgery at the start of the consultation. A patch is still a prescription treatment, and changing route yourself bypasses the assessment that makes the comparison useful.
  source ids
  society-ht-2022
  society-ht-patient
  p-shufelt
- label
  Review duration through a continuing reason for treatment
  text
  Some advice proposes a fixed stopping anniversary; other advice treats continued use as automatic. The Menopause Society instead ties longer use to documented indications, such as persistent vasomotor symptoms, with shared decisions and periodic reassessment. That leaves legitimate uncertainty about the best duration for different people and products. It does not make five years on treatment a universal stop rule or promise that indefinite treatment is risk-free. NICE recommends an initial treatment review at three months and subsequent annual review, with earlier review when symptoms, side effects or other concerns warrant it. Revisit the benefit you actually notice, new health conditions, the product and dose, and the reason to continue. A follow-up is part of care, not evidence that the first decision failed.
  source ids
  society-ht-2022
  nice-ng23
  p-christmas
- label
  Interpret a changed warning label without erasing individual risk
  text
  On February 12, 2026 the FDA announced approved labeling changes for an initial six menopausal hormone products, removing cardiovascular, breast-cancer and probable-dementia risk statements from their boxed warnings. This is a regulatory labeling change affecting specified products; it is not proof that all formulations have become risk-free or that the same label change applies to every product. Clinical evidence, the rest of the product label and your own contraindications still matter. The distinction also helps resolve apparent conflicts between an older leaflet and a newer announcement. Ask the prescriber or pharmacist to review the current label for the exact medicine. A warning's position on the label does not by itself establish a new indication for lifelong disease prevention.
  source ids
  fda-ht-labels-2026
  whi-review-2024
id
repair-the-night
role
findings
title
What helps when nights stay broken?
intro
Night sweats and insomnia can overlap. A useful assessment does not require one to explain the other completely.
items
- label
  Use the insomnia trial to understand what structured care can change
  text
  Susan McCurry and colleagues randomized 106 peri- or postmenopausal women aged 40–65 with insomnia and at least two daily hot flashes to six telephone CBT-I sessions or menopause education. CBT-I means cognitive behavioral therapy for insomnia: structured work on sleep timing, time in bed, habits and thoughts that sustain insomnia. After eight weeks, insomnia-severity scores fell by 9.9 points with CBT-I versus 4.7 with education; group differences remained at 24 weeks. Hot-flash counts did not differ, although interference improved. Better sleep did not require every heat episode to disappear. This was one selected, largely White study population, not a trial of every app or a proof that casual bedtime tips are equivalent. Ask about access to structured insomnia care rather than trying to recreate the trial's sleep restrictions alone.
  source ids
  mccurry-cbti
  p-mccurry
- label
  Keep breathing, mood and daytime function in the assessment
  text
  Repeated breathing pauses or gasping, loud snoring and unintended daytime sleepiness point toward a different sleep question from difficulty falling back asleep. NHLBI explains that sleep apnea can present with insomnia or fatigue in women as well as more familiar snoring symptoms. Depression, anxiety, medicines and other conditions can also belong in a clinical sleep history. Pauline Maki's menopause research examines mood and cognition, while Joffe's work connects midlife sleep and vasomotor symptoms. Those research connections support asking about the whole pattern; they do not diagnose the cause of your tiredness or a memory lapse. When heat treatment helps but sleep remains poor, the remaining problem is worth assessing on its own merits.
  source ids
  nhlbi-apnea
  p-maki
  p-joffe
id
bone-muscle-and-loading
role
findings
title
How bone and strength fit into midlife care
intro
Feeling stronger, improving a density measurement and preventing a fracture are related but different outcomes.
items
- label
  Understand why bone health deserves attention during the transition
  text
  Bone is living tissue that is continually renewed. Cells remove old material and other cells replace it. The Menopause Society's osteoporosis statement explains that estrogen decline can accelerate removal beyond replacement around the transition, producing a period of faster bone loss. This can happen even when someone feels well. Bone strength depends on density and structure, while whether a fall becomes a fracture also depends on other factors. A density test, a medicine and an exercise session therefore address overlapping rather than identical parts of the problem. Hormone therapy can prevent bone loss in suitable users, but established osteoporosis needs its own management discussion. A person who is active may still need fracture-risk assessment; a person with low density may still benefit from suitably adapted activity.
  source ids
  society-bone-2021
  society-bone-handout
- label
  Use risk and age to guide the bone-screening conversation
  text
  Bone mineral density measures how much mineral is present in a defined area of bone. A DXA scan is a low-dose X-ray test commonly used to measure it. Lower density can help identify osteoporosis, a condition associated with greater fracture risk, but density alone does not describe every reason a person may break a bone. USPSTF's 2025 recommendation is to screen women 65 or older, and postmenopausal women under 65 who are at increased risk after a clinical risk assessment. Factors include low body weight, a parent's hip fracture, smoking and excess alcohol use. This recommendation is for screening; people with known osteoporosis or a fragility fracture need assessment and management rather than a first-screening rule. Ask whether the recommendation fits your history.
  source ids
  uspstf-bone
- label
  Read heavy-lifting evidence together with its supervision
  text
  Belinda Beck and colleagues' LIFTMOR trial studied 101 screened postmenopausal women with low bone mass for eight months. It compared a twice-weekly, thirty-minute supervised program of high-intensity resistance and impact training with lower-intensity home exercise. The research protocol included five sets of five repetitions above 85% of a one-repetition maximum, meaning the greatest weight a person could lift once. Spine density increased about 2.9% in the supervised group versus a 1.2% decline in controls, with better functional performance and one reported minor back spasm. These details are the study exposure, not your starting workout. The short trial measured density and function, not proof of fewer lifetime fractures. Screening, coaching and progression were part of the intervention; unsupervised heavy lifting is a different exposure.
  source ids
  liftmor-2018
  p-beck
- label
  Choose repeatable movement for its own health outcomes
  text
  WHO's adult activity guidance includes strengthening all major muscle groups on at least two days each week, alongside aerobic activity; some activity is better than none. That population guidance is a useful direction, not a personal prescription or a demand to meet a heavy-lifting protocol immediately. Walking supports activity, while bone-targeted loading and resistance exercise ask different things of the body. Kohrt's research explains why estrogen, exercise, metabolism and body composition all belong in the midlife picture. If you already train, discuss whether your load, technique or supervision fits your health. If you are starting or have low bone mass, a qualified clinician or exercise professional can help adapt the work. Sudden severe pain or an injury needs assessment rather than a heavier session.
  source ids
  who-activity
  p-kohrt
  liftmor-2018
id
evaluate-treatment-claims
role
perspectives
title
How to judge competing treatment promises
intro
A disagreement in marketing is not automatically an unresolved scientific question. Ask what evidence would justify the specific promise.
items
- label
  Check the product evidence behind the word bioidentical
  text
  Bioidentical means that a molecule has the same chemical structure as a hormone made by the body. FDA-approved estradiol and micronized progesterone products can already meet that description. A compounded product is mixed to a prescription rather than approved as that finished formulation. The Endocrine Society says evidence does not establish that custom compounded hormone mixtures are safer or more effective, and warns about inconsistent dose and purity. The FDA's account of the National Academies review identifies weak clinical evidence and limited oversight as public-health concerns. This is a product-testing and quality question, not a contest between 'natural' and 'synthetic' words. A documented need for compounding, such as an ingredient allergy, is a clinician-pharmacy decision. The label alone does not justify replacing a regulated product.
  source ids
  endo-compounding
  fda-nasem
- label
  Ask what a saliva test has been shown to predict
  text
  A saliva hormone panel can look precise because it produces numbers and a customized-looking recipe. Precision of presentation is different from demonstrated clinical usefulness. The Endocrine Society explains that hormone levels vary with physiology and the way medicines are absorbed and processed, and that evidence does not validate saliva-based customization as a reliable dosing method. This is separate from a clinician ordering a test for a specific diagnostic question. Jen Gunter's public education helps readers recognize such gaps between a convincing story and tested medicine, but the supporting authority here is the professional statement. Bring symptoms, history and treatment goals to the prescriber. Ask what outcome the test-guided approach improves over ordinary care, and whether that comparison has actually been studied.
  source ids
  endo-compounding
  p-gunter
- label
  Keep exercise and comfort strategies tied to the result they can deliver
  text
  A fan, clothing changes, walking or yoga may make an episode or a day more manageable. The Menopause Society's 2023 evidence review did not recommend exercise, yoga, cooling or trigger-avoidance lists as proven vasomotor treatments. That is an outcome-specific conclusion, not a reason to abandon activity or something that improves your comfort. WHO's guidance still supports movement for health, and LIFTMOR tested loading for bone. Public advice becomes misleading when it turns those benefits into a guarantee that heat will stop. You can keep a helpful routine while seeking evidence-based symptom care if needed. Improvement in muscle or comfort does not establish a reduction in the frequency of hot flashes.
  source ids
  society-nonhormone-2023
  who-activity
  society-hot-flashes
- label
  Compare herbal promises with supported nonhormone choices
  text
  Black cohosh, soy extracts and mixed 'menopause support' products are often presented as gentler substitutes for treatment. The 2023 society review did not recommend supplements and herbal remedies for vasomotor symptoms because adequate, consistent benefit was not established. A soy food in an ordinary diet is a different question from using an extract as a hot-flash treatment. Supplements can have adverse effects and interactions; 'natural' does not answer those questions. Show a clinician or pharmacist the ingredients rather than assuming a blend's marketing name describes what it contains. If you prefer to avoid hormones, ask about the named nonhormone options with evidence. Heavy bleeding or severe sleep disruption deserves assessment while that choice is being considered.
  source ids
  society-nonhormone-2023
  society-nonhormone-handout
id
check-common-claims
role
findings
title
Check the claim before acting on it
intro
These verdicts concern the statement as written. Read the matching explanation above for the finding and its limits.
items
- label
  Use the twelve-month marker with its exceptions
  text
  Claim: 'Menopause means periods have stopped for twelve months.' Verdict: established for natural menopause when another cause or hormonal treatment does not explain the absence. Surgery and younger age can require a different assessment. The marker names a stage retrospectively; it does not decide whether symptoms deserve care before or after that point.
  source ids
  cms-stages
- label
  Allow a longer course for frequent heat
  text
  Claim: 'Frequent hot flashes usually last only a year or two.' Verdict: not supported as written. SWAN's median was 7.4 years among women with frequent symptoms. Some courses are shorter, others much longer. A group estimate corrects the fixed timer but does not determine your last episode.
  source ids
  avis-duration
- label
  Make hormone therapy an individual choice
  text
  Claim: 'Every woman in menopause should take hormone therapy.' Verdict: not supported as written. Treatment depends on symptoms, indications, history, contraindications and preferences. Hormones are an effective option for heat and have bone effects; those benefits do not create a universal mandate or a general prescription for lifelong disease prevention.
  source ids
  society-ht-handout
  whi-review-2024
- label
  Keep the WHI conclusion attached to what it tested
  text
  Claim: 'The WHI proved that no one should ever take hormones.' Verdict: not supported as written. The trials raised important regimen-specific risks for prevention. Current interpretation still allows symptom treatment in suitable women near menopause. Neither discarding the trial nor turning it into a lifetime ban faithfully represents the evidence.
  source ids
  whi-review-2024
- label
  Separate activity benefits from a heat-treatment guarantee
  text
  Claim: 'Exercise is a proven treatment for hot flashes.' Verdict: not supported as written. The society review did not recommend exercise as vasomotor therapy. Muscle, function and bone remain worthwhile reasons for activity. Choosing it for those reasons does not require claiming that it will switch off heat.
  source ids
  society-nonhormone-2023
  who-activity
- label
  Require evidence for a custom-product safety promise
  text
  Claim: 'Custom compounded bioidentical hormones are safer than approved products.' Verdict: not supported as written. The National Academies assessment found inadequate rigorous evidence and quality-oversight concerns. Body-identical molecules also exist in approved products. A custom label or saliva-derived recipe does not establish a safety advantage.
  source ids
  fda-nasem
- label
  Recognize structured insomnia care as a tested option
  text
  Claim: 'CBT-I can improve insomnia during the menopause transition.' Verdict: established. McCurry's randomized trial found better insomnia outcomes than menopause education through 24 weeks in women with insomnia and hot flashes. This supports the possibility of benefit; it is not a guarantee or a substitute for investigating breathing pauses.
  source ids
  mccurry-cbti
id
get-the-right-level-of-care
role
cautions
title
When to seek assessment promptly
intro
A diary helps an appointment. It should never postpone assessment of concerning symptoms.
items
- label
  Have new or unusual bleeding assessed
  text
  Bleeding or spotting after natural menopause should be reported even if it happens only once or is a small amount. NHS guidance explains that it is often not serious but can sometimes signal a condition needing treatment, including cancer. Very heavy or unusually frequent bleeding during the transition also deserves assessment; it should not automatically be attributed to hormone fluctuation. HRT adds another distinction: some regimens intentionally produce scheduled bleeding, and NICE's April 2026 guidance notes that unscheduled bleeding can occur early after starting or changing systemic HRT. Beyond the specified adjustment periods, prompt medical help is advised. Discuss any new, persistent or concerning bleeding with the prescriber rather than deciding for yourself that it is expected or waiting out a rule from this article.
  source ids
  nhs-postmenopausal-bleeding
  nhs-heavy-bleeding
  nice-ng23
- label
  Use emergency help for sudden severe symptoms
  text
  Chest pain, fainting, sudden breathlessness or one-sided weakness should not be dismissed as a hot flash or ordinary midlife change. NIH heart-attack guidance and CDC stroke guidance emphasize prompt emergency assessment for relevant warning symptoms; call local emergency services, including 911 in the United States, when they occur. Severe bleeding with collapse or marked weakness also needs urgent help. This distinction protects the usefulness of ordinary symptom tracking: gradual patterns can inform a scheduled visit, while sudden severe changes need immediate attention. A page cannot determine which diagnosis explains the event. Do not wait to finish a diary or see whether a supplement, hormone dose or workout changes it.
  source ids
  nhlbi-heart
  cdc-stroke
  nhs-heavy-bleeding
- label
  Use this reading to prepare for care
  text
  This is a reading companion, not a diagnosis, hormone prescription, or clinic visit. Persistent or bothersome heat, night sweats, broken sleep, early period stop, or worry about bone belong with a qualified clinician who can take a history and tailor care. After more than a year without a period, new bleeding or spotting needs prompt medical review. Periods that stop before 45, very heavy or closely stacked bleeding, and sudden severe symptoms also need a person, not a page. Do not start, stop, or change hormone therapy, other medicines, or a training plan from this text. Chest pain, fainting, one-sided weakness, or sudden breathlessness need emergency care. This page does not treat one body or promise an outcome. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.
  source ids
  nice-ng23
  cms-stages
  nhs-postmenopausal-bleeding
  nhlbi-heart
  cdc-stroke
id
prepare-one-useful-visit
role
next_steps
title
Bring one clear question to your next visit
intro
Choose the problem that matters most, while mentioning the others that may affect the decision.
items
- label
  Bring four lines that tell the clinician what has changed
  text
  Write a brief account of your cycle pattern, daytime heat or night sweats, sleep and daytime function, and the issue you want help with first. Add current medicines and supplements, relevant surgery, and any fracture, clot, cancer, liver or cardiovascular history. This translates the clinical-history approach used by NICE into a practical visit aid; it is not a diagnostic checklist. You might bring, 'My cycles have changed, heat wakes me, and I want to understand sleep and treatment options.' Ask what else should be assessed and which treatment outcome would count as worthwhile improvement. You do not need to resolve the hormone debate before requesting a conversation.
  source ids
  nice-ng23
  society-ht-handout
  p-faubion
- label
  Try a short diary that records interference
  text
  For a few ordinary weeks, note bleeding dates, a rough heat count, night sweats and whether they interrupted activity or sleep. Use simple words rather than treating the diary as a research-grade instrument. The field distinguishes frequency from interference, so include what you could not do or how long returning to sleep took. Bring what you have even if recording is incomplete. This is a suggested communication aid drawn from the kinds of outcomes researchers measure, not a validated home test or a requirement to delay care. New postmenopausal bleeding, very heavy bleeding or sudden severe symptoms belong in the care pathways above.
  source ids
  society-hot-flashes
  menos-trials
  nhs-postmenopausal-bleeding
- label
  Try a specific question about sleep care
  text
  If insomnia is the main problem, ask where you can access CBT-I and whether a separate sleep assessment is indicated. Mention heat, gasping or breathing pauses, mood and medicines so the clinician can consider overlapping causes. McCurry's research supports structured care delivered by telephone in a defined group, rather than the idea that everyone must reach an in-person specialist before anything can help. Availability, cost and the suitability of a program still need checking locally. If heat improves but sleep does not, bring that result back; it helps clarify the next question. For how people talk about sleep hours, see STUDself at /self/. Its experience map does not replace clinical sleep assessment.
  source ids
  mccurry-cbti
  nhlbi-apnea
  p-mccurry
- label
  Try a specific question about bone and supervised activity
  text
  Ask whether bone screening is due for your age and risk, and which kind of strength or impact activity fits your current health. Say what you already do; suitable progression is more useful than copying a study's maximum load. The screening recommendation and lifting trial answer different questions, so requesting one conversation does not commit you to either a scan or a high-intensity program. Agree on what symptoms or changes would prompt reassessment. For lifting after 40, see STUDfit at /fit/ for the community discussion. Keep exercise as health work, symptom treatment as a reviewed choice, and follow-up as an ordinary part of care.
  source ids
  uspstf-bone
  liftmor-2018
  who-activity

related

sleep
fitness
anxiety

sources

id
who-menopause
title
Menopause
url
https://www.who.int/news-room/fact-sheets/detail/menopause
kind
official
accessed at
2026-10-01
supports
Explains ovarian follicular loss, the twelve-month definition of natural menopause, variable symptoms and perimenopause.
limitations
Public education rather than a diagnostic or treatment algorithm.
id
endo-menopause
title
Menopause — Endocrine Library
url
https://www.endocrine.org/patient-engagement/endocrine-library/menopause
kind
professional
accessed at
2026-10-01
supports
Explains fluctuating hormones, changing cycle patterns and the role of clinical history in assessing atypical symptoms. Nanette Santoro is among its named clinical editors.
limitations
Page last updated January 24, 2022. Used for basic explanation, not an up-to-date medicine list or its simplified causal claims about mood.
id
mayo-menopause
title
Menopause — Symptoms and causes
url
https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397
kind
professional
accessed at
2026-10-01
supports
Gives an average U.S. menopause age of 51 and distinguishes hysterectomy with ovaries remaining from removal of the ovaries.
limitations
A public summary; individual variation and other possible causes still require clinical assessment.
id
straw-2012
title
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging
url
https://integration.sart.org/globalassets/_asrm/practice-guidance/practice-guidelines/pdf/executive-summary-of-the-straw.pdf
kind
guideline
accessed at
2026-10-01
supports
Defines the persistent seven-day cycle difference, sixty-day gap, late-transition duration and endpoint of perimenopause used in reproductive-aging staging.
limitations
Research and clinical staging consensus rather than home diagnosis; medication-masked bleeding and special populations need different assessment.
id
cms-stages
title
Definition and Stages
url
https://www.canadianmenopausesociety.org/professionals/menopause-hub/definition/
kind
professional
accessed at
2026-10-01
supports
Defines menopause retrospectively, distinguishes stage from symptoms, and explains when medical interventions or other causes complicate the definition.
limitations
Professional overview, not a personalized diagnostic test. Population definitions should not delay abnormal-bleeding care.
id
nice-ng23
title
Menopause: identification and management — Recommendations (NG23)
url
https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
kind
guideline
accessed at
2026-10-01
supports
Sections 1.3.1–1.3.6 address clinical identification and testing; sections 1.8.4–1.8.5 address bleeding after systemic HRT; section 1.9 covers treatment review. The April 2026 bleeding guidance distinguishes the first six months after starting HRT and the first three months after a dose or preparation change from bleeding beyond those intervals, when prompt help is advised.
limitations
UK clinical guidance, not U.S. prescribing instructions. Full guideline/evidence collection not read cover to cover. Expected bleeding does not mean all bleeding can be ignored.
id
poi-guideline
title
Evidence-based guideline: Premature Ovarian Insufficiency
url
https://www.asrm.org/practice-guidance/practice-committee-documents/evidence-based-guideline-premature-ovarian-insufficiency--2024/
kind
guideline
accessed at
2026-10-01
supports
International guidance on before-40 POI, early menopause 40–44, intermittent ovarian activity in nonsurgical POI, distinct health/fertility needs and HT through usual menopause age. Current page title marks 2025; literature search ended January 30, 2024.
limitations
Many POI-specific options have limited evidence; clinician assessment required. This article uses it to explain the condition and the need for individualized care.
id
avis-duration
title
Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
url
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2110996
kind
study
accessed at
2026-10-01
supports
Reports SWAN analysis of 1,449 frequent-symptom participants; 7.4-year median, 4.5 years after final period among 881; earlier onset and group duration differences.
limitations
Observational, self-reported symptoms on at least six of prior fourteen days; selected symptomatic population. Medians and group associations are not personal predictions or proof of causation.
id
society-hot-flashes
title
Hot Flashes
url
https://menopause.org/patient-education/menopause-topics/hot-flashes
kind
professional
accessed at
2026-10-01
supports
Explains hot-flash and night-sweat definition, variation and symptom-management questions.
limitations
Public education. Comfort suggestions are not upgraded to trial-proven vasomotor therapy.
id
menos-trials
title
CBT effective in treating menopause symptoms
url
https://www.kcl.ac.uk/archive/news/ioppn/records/2012/feb/cbt-menopause
kind
official
accessed at
2026-10-01
supports
The investigators' institutional report describes MENOS1 (96 breast-cancer survivors) and MENOS2 (140 otherwise healthy women): improved problem ratings through 26 weeks.
limitations
An institutional trial report rather than a review of the complete journal methods; it does not support a guarantee of no side effects.
id
crandall-review
title
Management of Menopausal Symptoms: A Review
url
https://jamanetwork.com/journals/jama/article-abstract/2801054
kind
review
accessed at
2026-10-01
supports
The 2023 review abstract reports 50%–75% VMS prevalence during transition; approximate 75% average frequency reduction with systemic estrogen; treatment and prevention distinction.
limitations
Abstract inspected, not paywalled full text; pooled estimates, not individual benefit or head-to-head ranking. The discussion here concerns vasomotor symptoms.
id
society-ht-2022
title
The 2022 hormone therapy position statement of The North American Menopause Society
url
https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
kind
guideline
accessed at
2026-10-01
supports
Addresses routes, contraindications, bone benefits, age, timing and duration. It describes a generally favorable balance for suitable symptomatic women under 60 or within ten years of menopause onset, without contraindications.
limitations
2022 consensus, not a new trial or updated product label. Evidence varies by formulation and route; no large route-comparison outcome RCT claimed. Not all 28 pages read line by line.
id
society-ht-handout
title
Deciding About Hormone Therapy Use
url
https://menopause.org/wp-content/uploads/default-document-library/MenoNote-Deciding-About-HT-2025.pdf
kind
professional
accessed at
2026-10-01
supports
A two-page society handout about symptom decisions, uterus/progestogen considerations and individualized review.
limitations
2025 educational handout, not a prescription or evidence of a universal duration rule.
id
society-ht-patient
title
Menopause Topics: Hormone Therapy
url
https://menopause.org/patient-education/menopause-topics/hormone-therapy
kind
professional
accessed at
2026-10-01
supports
Explains systemic treatment, endometrial protection when uterus present and possible route-related clot-risk difference.
limitations
Public simplifications and exact cancer-year claims are not reproduced as universal safety thresholds. Original trials and position statement govern nuanced comparison.
id
society-nonhormone-2023
title
The 2023 nonhormone therapy position statement of The North American Menopause Society
url
https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
kind
guideline
accessed at
2026-10-01
supports
Sets out recommended interventions and evidence tiers; exercise/yoga/cooling/supplement conclusions are specific to vasomotor outcomes.
limitations
Predates December 2024 fezolinetant boxed warning and October 2025 elinzanetant approval. No DIY prescribing, combination plan or assumption that nonhormone means harmless.
id
society-nonhormone-handout
title
Nonhormone Treatments for Hot Flashes and Night Sweats
url
https://menopause.org/wp-content/uploads/default-document-library/nonhormone-treatment-menonote_f5afc19f-211e-4c1f-8a04-b2d558c6fa66.pdf
kind
professional
accessed at
2026-10-01
supports
Distinguishes supported nonhormone options from popular approaches.
limitations
Patient education; no guarantee, dosage plan or complete current-label review.
id
fda-veozah-safety
title
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
url
https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
kind
official
accessed at
2026-10-01
supports
The December 16, 2024 boxed-warning update specifies liver tests before treatment, monthly for the first three months, and at months six and nine, plus an urgent response to liver-injury symptoms.
limitations
Historical safety communication as hosted October 1, 2026; not represented as latest complete prescribing label. Current exact product instructions remain prescriber's responsibility.
id
fda-veozah-label
title
VEOZAH (fezolinetant) tablets — prescribing information, revised December 2024
url
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf
kind
official
accessed at
2026-10-01
supports
Contains the boxed liver-injury warning and monitoring requirements described in the safety update.
limitations
Explicitly December 2024 label, not claimed to be newest complete label; no dose recommendations in article.
id
fda-lynkuet-snapshot
title
Drug Trials Snapshots: LYNKUET
url
https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lynkuet
kind
official
accessed at
2026-10-01
supports
Documents October 24, 2025 approval; OASIS efficacy participants and episode criteria; approximately 3.2 extra daily episodes reduced versus placebo at week twelve; age and subgroup limitations.
limitations
An original-approval snapshot rather than the latest label or a head-to-head treatment comparison. The age tables report a range of 40–65, while the summary gives a conflicting cutoff; this article uses the tabulated range. The snapshot's incorrect link to an unrelated drug label was excluded.
id
fda-lynkuet-label
title
LYNKUET (elinzanetant) capsules — prescribing information, revised October 2025
url
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf
kind
official
accessed at
2026-10-01
supports
The original approval label describes NK1/NK3 mechanism, baseline and three-month liver assessment, daytime impairment, interactions and pregnancy contraindication.
limitations
Original approval label, not claimed newest complete label. No doses or self-management protocol proposed; current product assessment belongs to prescriber.
id
whi-2002
title
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
url
https://jamanetwork.com/journals/jama/fullarticle/195120
kind
study
accessed at
2026-10-01
supports
Reports 16,608 participants, ages 50–79, specific oral CEE/MPA doses, 5.2-year follow-up, stopped prevention trial, major harms/benefits and absolute breast-cancer excess.
limitations
One regimen and prevention population with mean age around 63; does not test every modern formulation or establish a universal ban. Selected relevant report sections inspected.
id
whi-followup-2013
title
Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials
url
https://jamanetwork.com/journals/jama/fullarticle/1745676
kind
study
accessed at
2026-10-01
supports
Reviews thirteen years of findings from both randomized trials, including combined/estrogen-alone breast patterns and absolute-event differences by age.
limitations
Age subgroup interpretation and extended follow-up have limits; not a new randomized test of early modern therapy. Different regimens and uterine-status populations remain separate.
id
whi-review-2024
title
The Women's Health Initiative Randomized Trials and Clinical Practice: A Review
url
https://jamanetwork.com/journals/jama/article-abstract/2818206
kind
review
accessed at
2026-10-01
supports
The review abstract concludes that WHI does not support HT for cardiovascular/other chronic-disease prevention; symptom care in suitable early-menopause women remains appropriate.
limitations
Abstract inspected, not entire paywalled review. Does not establish a preventive indication for all formulations or prescribe for visitors.
id
fda-ht-labels-2026
title
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
url
https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
kind
official
accessed at
2026-10-01
supports
The February 12, 2026 announcement describes initial six products' approved boxed-warning changes and distinction from November 2025 request.
limitations
Regulatory announcement, not a new trial, a record of all subsequent product changes or proof of absent risk. Broader promotional prevention interpretations not adopted.
id
mccurry-cbti
title
Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial
url
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2522398
kind
study
accessed at
2026-10-01
supports
Reports 106 participants, six telephone sessions, insomnia-score changes 9.9 versus 4.7 at eight weeks, sustained differences at 24 weeks, unchanged between-group flash frequency.
limitations
Single-site, selected largely White group; no apnea treatment, app equivalence, permanent cure or self-directed sleep-restriction plan claimed.
id
nhlbi-apnea
title
Sleep Apnea — Symptoms
url
https://www.nhlbi.nih.gov/health/sleep-apnea/symptoms
kind
official
accessed at
2026-10-01
supports
Explains why breathing pauses/gasping/snoring, daytime symptoms and presentation in women justify a separate assessment.
limitations
Symptom education, not home diagnosis. Sleep-study and treatment instructions excluded.
id
society-bone-2021
title
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
url
https://menopause.org/wp-content/uploads/professional/2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf
kind
guideline
accessed at
2026-10-01
supports
Explains bone remodeling imbalance with estrogen decline; density versus strength/fracture; individualized management.
limitations
2021 North American consensus; no personal osteoporosis-treatment algorithm. Current screening age/risk recommendations sourced separately to USPSTF 2025.
id
society-bone-handout
title
Postmenopausal Osteoporosis — MenoNote
url
https://menopause.org/wp-content/uploads/professional/menonote-osteoporosis.pdf
kind
professional
accessed at
2026-10-01
supports
Explains bone risk and osteoporosis for patients.
limitations
Educational summary, not an individualized scan, drug or exercise decision.
id
uspstf-bone
title
Osteoporosis to Prevent Fractures: Screening
url
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
kind
guideline
accessed at
2026-10-01
supports
The January 2025 recommendation addresses women 65+; younger postmenopausal women at increased risk following clinical assessment; DXA; risk factors and exclusions.
limitations
Population screening guidance excludes known osteoporosis/fragility-fracture cases. Does not prescribe treatment or give a personal FRAX threshold.
id
liftmor-2018
title
High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial
url
https://pubmed.ncbi.nlm.nih.gov/28975661/
kind
study
accessed at
2026-10-01
supports
The primary abstract describes 101 screened participants in an eight-month supervised trial, including five sets of five repetitions above 85% of one-repetition maximum, changes in spine density and one minor back spasm.
limitations
This account relies on the abstract; full text was unavailable for review. The small, selected and supervised study does not establish a reduction in fractures or the safety of unsupervised lifting.
id
who-activity
title
Physical activity
url
https://www.who.int/news-room/fact-sheets/detail/physical-activity
kind
official
accessed at
2026-10-01
supports
Describes adult aerobic and muscle-strengthening guidance, including work for major muscle groups on two or more days and the value of some activity over none.
limitations
Population recommendation, not a menopause-treatment trial or individual gym program; full guideline PDF not claimed read.
id
endo-compounding
title
Compounded Bioidentical Hormone Therapy
url
https://www.endocrine.org/advocacy/position-statements/compounded-bioidentical-hormone-therapy
kind
guideline
accessed at
2026-10-01
supports
The 2019 statement addresses molecule definition, approved body-identical products, lack of superiority evidence, variable quality and unsupported saliva customization.
limitations
Position statement, not a new outcomes trial. Does not deny documented clinical compounding needs or adjudicate every pharmacy.
id
fda-nasem
title
National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy
url
https://www.fda.gov/drugs/human-drug-compounding/national-academies-science-engineering-and-medicine-nasem-study-clinical-utility-treating-patients
kind
official
accessed at
2026-10-01
supports
The FDA's summary of the independent July 2020 report describes lack of rigorous clinical safety/effectiveness evidence and limited oversight.
limitations
Official report summary, not complete 2020 book; absence of superiority evidence is not proof that every compounded preparation always causes harm.
id
nhs-postmenopausal-bleeding
title
Postmenopausal bleeding
url
https://www.nhs.uk/symptoms/post-menopausal-bleeding/
kind
official
accessed at
2026-10-01
supports
The NHS page, reviewed September 24, 2026, explains assessment needed even for one small episode, common benign causes and potential cancer relevance.
limitations
UK public triage information; not a cancer diagnosis, a universal HRT-bleeding rule or a U.S. referral-time guarantee.
id
nhs-heavy-bleeding
title
Heavy periods
url
https://www.nhs.uk/conditions/heavy-periods/
kind
official
accessed at
2026-10-01
supports
Explains symptoms and assessment of heavy periods and bleeding changes.
limitations
Public education; no home bleeding diagnosis or treatment algorithm. Urgent symptoms still require clinical assessment.
id
nhlbi-heart
title
Heart Attack — Symptoms
url
https://www.nhlbi.nih.gov/health/heart-attack/symptoms
kind
official
accessed at
2026-10-01
supports
Explains warning symptoms and the need for prompt emergency help.
limitations
Does not mean every chest symptom is a heart attack; used for escalation, not diagnosis.
id
cdc-stroke
title
Signs and Symptoms of Stroke
url
https://www.cdc.gov/stroke/signs-symptoms/index.html
kind
official
accessed at
2026-10-01
supports
The May 19, 2026 CDC guidance explains why sudden one-sided weakness and other stroke symptoms require immediate emergency help.
limitations
Used only for emergency escalation; no stroke risk score or differential diagnosis.
id
question-hrt-cbt
title
HRT guidance update UK — r/Menopause discussion
url
https://www.reddit.com/r/Menopause/comments/1glpjxt/hrt_guidance_update_uk/
kind
question_signal
accessed at
2026-10-01
supports
Discussion illustrates confusion about whether talking therapy complements or replaces hormones, and why symptom frequency, interference and treatment choice need to be distinguished.
limitations
Qualitative self-selected discussion, including unsupported prevention claims; no comment is factual medical authority or representative prevalence evidence.
id
question-guidance-access
title
Hormone therapy recommendations — r/Menopause discussion
url
https://www.reddit.com/r/Menopause/comments/1dfctw9/hormone_therapy_recommendations_thought_folks/
kind
question_signal
accessed at
2026-10-01
supports
Discussion illustrates how people use professional recommendations when seeking care, informing the article's appointment preparation.
limitations
A qualitative source of reader questions, not medical evidence; treatment claims rely on the professional sources cited separately.
id
p-faubion
title
Stephanie S. Faubion — official professional profile
url
https://www.mayoclinic.org/biographies/faubion-stephanie-s-m-d-m-b-a/bio-20054845
kind
professional
accessed at
2026-10-01
supports
MD, MBA; Mayo Clinic internist and director of its Center for Women's Health. Mayo's public biography includes an accessible explanation of midlife symptoms and clinical education. Research findings are supported by the studies and guidelines cited separately.
limitations
A clinical leader's public explanation is not a prescription or a trial of every regimen.
id
p-manson
title
JoAnn E. Manson — official professional profile
url
https://www.health.harvard.edu/authors/joann-manson-md-drph
kind
professional
accessed at
2026-10-01
supports
MD, DrPH; Harvard professor of medicine and Brigham and Women's Hospital chief of preventive medicine. Harvard public-health writing and WHI reviews translate the prevention findings into clinical questions. Research findings are supported by the studies and guidelines cited separately.
limitations
WHI regimens and populations do not represent every modern therapy; public education is not individualized care.
id
p-santoro
title
Nanette F. Santoro — official professional profile
url
https://medschool.cuanschutz.edu/ob-gyn/divisions/division-of-reproductive-sciences/our-faculty/nanette-santoro-md
kind
professional
accessed at
2026-10-01
supports
MD; E. Stewart Taylor Professor of Obstetrics and Gynecology, University of Colorado Anschutz. Public university research description and professional menopause education explain changing ovarian function. Research findings are supported by the studies and guidelines cited separately.
limitations
Fluctuating physiology cannot date one reader's final period or turn one blood test into a verdict.
id
p-thurston
title
Rebecca C. Thurston — official professional profile
url
https://www.psychiatry.pitt.edu/about-us/our-people/rebecca-c-thurston-phd
kind
professional
accessed at
2026-10-01
supports
PhD; Pittsburgh Foundation Chair in Women's Health and Dementia and Distinguished Professor of Psychiatry, University of Pittsburgh. Official research biography and selected publications explain vasomotor symptoms in relation to daily life and health. Research findings are supported by the studies and guidelines cited separately.
limitations
Observational associations do not prove that treating flashes prevents cardiovascular disease.
id
p-joffe
title
Hadine Joffe — official professional profile
url
https://bidmc.org/departments-divisions/psychiatry/team
kind
professional
accessed at
2026-10-01
supports
MD, MSc; Chair and Chief of Psychiatry, Beth Israel Deaconess Medical Center. Public institutional role and authored menopause/sleep research bring mood, insomnia and heat into one assessable picture. Research findings are supported by the studies and guidelines cited separately.
limitations
Current role is BIDMC; older Brigham/Connors affiliations in prior publications are historical. Research does not diagnose a reader.
id
p-maki
title
Pauline M. Maki — official professional profile
url
https://chicago.medicine.uic.edu/profiles/maki-pauline/
kind
professional
accessed at
2026-10-01
supports
PhD; Professor of Psychiatry, Psychology and Obstetrics and Gynecology; Senior Director of Research, UIC Center for Research on Women and Gender. Official profile describes menopause, cognition and mood research and professional guideline contributions. Research findings are supported by the studies and guidelines cited separately.
limitations
Cognitive complaints and depression need their own assessment; no dementia-prevention indication is inferred.
id
p-harlow
title
Siobán D. Harlow — official professional profile
url
https://sph.umich.edu/faculty-profiles/harlow-sioban.html
kind
professional
accessed at
2026-10-01
supports
PhD; Professor Emerita of Epidemiology and Obstetrics and Gynecology, University of Michigan. Public research profile explains SWAN and the internationally used reproductive-aging staging system. Research findings are supported by the studies and guidelines cited separately.
limitations
Research stages provide a common language rather than a personal diagnostic algorithm.
id
p-shufelt
title
Chrisandra L. Shufelt — official professional profile
url
https://www.mayo.edu/research/faculty/shufelt-chrisandra-l-m-d/bio-20542101
kind
professional
accessed at
2026-10-01
supports
MD, MS; Mayo Clinic women's-health and cardiovascular-hormone researcher. Official research description and society guidance make nonhormone options and vascular questions accessible. Research findings are supported by the studies and guidelines cited separately.
limitations
The 2023 recommendations predate later drug approvals and safety changes; route evidence has randomized-trial limits.
id
p-crandall
title
Carolyn J. Crandall — official professional profile
url
https://www.uclahealth.org/cancer/members/carolyn-crandall
kind
professional
accessed at
2026-10-01
supports
MD, MS; UCLA professor of medicine and internal-medicine physician. Official profile and JAMA clinical reviews explain treatment evidence without requiring a headline-level conclusion. Research findings are supported by the studies and guidelines cited separately.
limitations
Review estimates are group results, not personal efficacy promises; breast findings stay attached to the regimen.
id
p-kohrt
title
Wendy M. Kohrt — official professional profile
url
https://medschool.cuanschutz.edu/center-for-womens-health-research/about-us/faculty-leadership/wendy-kohrt
kind
professional
accessed at
2026-10-01
supports
PhD; Distinguished Professor in Geriatric Medicine and Nancy Anschutz Chair in Women's Health Research, University of Colorado Anschutz. University profile and public muscle-health education explain how exercise and estrogen affect midlife physiology. Research findings are supported by the studies and guidelines cited separately.
limitations
Physiology research does not establish one gym prescription or make exercise a vasomotor treatment.
id
p-beck
title
Belinda R. Beck — official professional profile
url
https://www.griffith.edu.au/griffith-health/school-allied-health-sport-social-work/research/exercise-science-research
kind
professional
accessed at
2026-10-01
supports
Professor of bone and exercise research, Griffith University. Official exercise-science team page describes bone-health research and its translation into clinical services. Research findings are supported by the studies and guidelines cited separately.
limitations
Small supervised trial is not proof of fracture prevention or safety of unsupervised lifting; clinical services are not themselves independent trials.
id
p-hunter
title
Myra S. Hunter — official professional profile
url
https://www.kcl.ac.uk/people/myra-hunter
kind
professional
accessed at
2026-10-01
supports
PhD; Emeritus Professor of Clinical Health Psychology, King's College London. Public biography describes menopause-focused CBT trials, books and self-help manuals. Research findings are supported by the studies and guidelines cited separately.
limitations
CBT does not mean symptoms are imagined, nor does it replace assessment or every other treatment.
id
p-gunter
title
Jen Gunter — official professional profile
url
https://www.ted.com/speakers/jen_gunter
kind
professional
accessed at
2026-10-01
supports
MD; obstetrician-gynecologist and pain-medicine physician, as identified by TED. TED's official speaker biography and Body Stuff public education address menopause myths and treatment language. Research findings are supported by the studies and guidelines cited separately.
limitations
Public communication is not primary trial evidence. The cited TED biography supports the role described here; a current Kaiser affiliation was not established.
id
p-christmas
title
Monica Christmas — official professional profile
url
https://www.uchicagomedicine.org/find-a-physician/physician/monica-christmas
kind
professional
accessed at
2026-10-01
supports
MD; University of Chicago obstetrician-gynecologist, director of its menopause program and Center for Women's Integrated Health. Official physician profile and public Q&A explain how symptom care differs across patients. Research findings are supported by the studies and guidelines cited separately.
limitations
Her inclusion does not imply endorsement of this article or establish one treatment duration for all readers.
id
p-avis
title
Nancy E. Avis — official professional profile / primary research authorship
url
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2110996
kind
professional
accessed at
2026-10-01
supports
PhD; SWAN investigator and lead author of the vasomotor-duration analysis. The primary report's accessible duration findings replace the common one- or two-year expectation. Research findings are supported by the studies and guidelines cited separately.
limitations
Primary-paper role verified; current faculty appointment is not claimed. Cohort medians do not predict one person's course.
id
p-mccurry
title
Susan M. McCurry — official professional profile
url
https://nursing.uw.edu/person/4376497-susan-m-mccurry/
kind
professional
accessed at
2026-10-01
supports
PhD; Research Professor Emeritus, University of Washington School of Nursing. Official profile describes clinical psychology and sleep research in older adults and people with coexisting conditions, including menopause. Research findings are supported by the studies and guidelines cited separately.
limitations
Selected clinical trial does not establish equivalence of an app, unsupervised sleep restriction or apnea treatment.

professional panel

name
Stephanie S. Faubion
credential
MD, MBA; Mayo Clinic internist and director of its Center for Women's Health
official url
https://www.mayoclinic.org/biographies/faubion-stephanie-s-m-d-m-b-a/bio-20054845
public usefulness
Mayo's public biography includes an accessible explanation of midlife symptoms and clinical education.
contribution
Chaired the 2022 hormone-therapy advisory panel; helps distinguish symptom treatment from a mandate.
boundary
A clinical leader's public explanation is not a prescription or a trial of every regimen.
reviewed at
2026-10-01
name
JoAnn E. Manson
credential
MD, DrPH; Harvard professor of medicine and Brigham and Women's Hospital chief of preventive medicine
official url
https://www.health.harvard.edu/authors/joann-manson-md-drph
public usefulness
Harvard public-health writing and WHI reviews translate the prevention findings into clinical questions.
contribution
WHI intervention and follow-up work makes regimen, age and absolute risk visible.
boundary
WHI regimens and populations do not represent every modern therapy; public education is not individualized care.
reviewed at
2026-10-01
name
Nanette F. Santoro
credential
MD; E. Stewart Taylor Professor of Obstetrics and Gynecology, University of Colorado Anschutz
official url
https://medschool.cuanschutz.edu/ob-gyn/divisions/division-of-reproductive-sciences/our-faculty/nanette-santoro-md
public usefulness
Public university research description and professional menopause education explain changing ovarian function.
contribution
Reproductive-aging and hormone-pattern research informs the clinical story behind cycle variation.
boundary
Fluctuating physiology cannot date one reader's final period or turn one blood test into a verdict.
reviewed at
2026-10-01
name
Rebecca C. Thurston
credential
PhD; Pittsburgh Foundation Chair in Women's Health and Dementia and Distinguished Professor of Psychiatry, University of Pittsburgh
official url
https://www.psychiatry.pitt.edu/about-us/our-people/rebecca-c-thurston-phd
public usefulness
Official research biography and selected publications explain vasomotor symptoms in relation to daily life and health.
contribution
Studies physiological hot flashes, sleep and cardiovascular-health relationships.
boundary
Observational associations do not prove that treating flashes prevents cardiovascular disease.
reviewed at
2026-10-01
name
Hadine Joffe
credential
MD, MSc; Chair and Chief of Psychiatry, Beth Israel Deaconess Medical Center
official url
https://bidmc.org/departments-divisions/psychiatry/team
public usefulness
Public institutional role and authored menopause/sleep research bring mood, insomnia and heat into one assessable picture.
contribution
Coauthor of the MsFLASH insomnia trial; helps separate overlapping causes of a disrupted night.
boundary
Current role is BIDMC; older Brigham/Connors affiliations in prior publications are historical. Research does not diagnose a reader.
reviewed at
2026-10-01
name
Pauline M. Maki
credential
PhD; Professor of Psychiatry, Psychology and Obstetrics and Gynecology; Senior Director of Research, UIC Center for Research on Women and Gender
official url
https://chicago.medicine.uic.edu/profiles/maki-pauline/
public usefulness
Official profile describes menopause, cognition and mood research and professional guideline contributions.
contribution
Makes mood and cognitive complaints part of a clinical assessment rather than an automatic hormone explanation.
boundary
Cognitive complaints and depression need their own assessment; no dementia-prevention indication is inferred.
reviewed at
2026-10-01
name
Siobán D. Harlow
credential
PhD; Professor Emerita of Epidemiology and Obstetrics and Gynecology, University of Michigan
official url
https://sph.umich.edu/faculty-profiles/harlow-sioban.html
public usefulness
Public research profile explains SWAN and the internationally used reproductive-aging staging system.
contribution
Led STRAW+10 staging, including the seven-day and sixty-day cycle criteria.
boundary
Research stages provide a common language rather than a personal diagnostic algorithm.
reviewed at
2026-10-01
name
Chrisandra L. Shufelt
credential
MD, MS; Mayo Clinic women's-health and cardiovascular-hormone researcher
official url
https://www.mayo.edu/research/faculty/shufelt-chrisandra-l-m-d/bio-20542101
public usefulness
Official research description and society guidance make nonhormone options and vascular questions accessible.
contribution
Led the 2023 nonhormone statement; studies cardiovascular effects of hormonal environments.
boundary
The 2023 recommendations predate later drug approvals and safety changes; route evidence has randomized-trial limits.
reviewed at
2026-10-01
name
Carolyn J. Crandall
credential
MD, MS; UCLA professor of medicine and internal-medicine physician
official url
https://www.uclahealth.org/cancer/members/carolyn-crandall
public usefulness
Official profile and JAMA clinical reviews explain treatment evidence without requiring a headline-level conclusion.
contribution
Synthesizes vasomotor treatments and investigates bone and breast outcomes in WHI.
boundary
Review estimates are group results, not personal efficacy promises; breast findings stay attached to the regimen.
reviewed at
2026-10-01
name
Wendy M. Kohrt
credential
PhD; Distinguished Professor in Geriatric Medicine and Nancy Anschutz Chair in Women's Health Research, University of Colorado Anschutz
official url
https://medschool.cuanschutz.edu/center-for-womens-health-research/about-us/faculty-leadership/wendy-kohrt
public usefulness
University profile and public muscle-health education explain how exercise and estrogen affect midlife physiology.
contribution
Studies estrogen, activity, body composition and bone; supports separating strength goals from hot-flash relief.
boundary
Physiology research does not establish one gym prescription or make exercise a vasomotor treatment.
reviewed at
2026-10-01
name
Belinda R. Beck
credential
Professor of bone and exercise research, Griffith University
official url
https://www.griffith.edu.au/griffith-health/school-allied-health-sport-social-work/research/exercise-science-research
public usefulness
Official exercise-science team page describes bone-health research and its translation into clinical services.
contribution
LIFTMOR investigator who tested screened, supervised heavy loading for low bone mass.
boundary
Small supervised trial is not proof of fracture prevention or safety of unsupervised lifting; clinical services are not themselves independent trials.
reviewed at
2026-10-01
name
Myra S. Hunter
credential
PhD; Emeritus Professor of Clinical Health Psychology, King's College London
official url
https://www.kcl.ac.uk/people/myra-hunter
public usefulness
Public biography describes menopause-focused CBT trials, books and self-help manuals.
contribution
MENOS trials show how CBT can reduce the problem rating of heat even when episode frequency is a different outcome.
boundary
CBT does not mean symptoms are imagined, nor does it replace assessment or every other treatment.
reviewed at
2026-10-01
name
Jen Gunter
credential
MD; obstetrician-gynecologist and pain-medicine physician, as identified by TED
official url
https://www.ted.com/speakers/jen_gunter
public usefulness
TED's official speaker biography and Body Stuff public education address menopause myths and treatment language.
contribution
Public communication helps distinguish 'bioidentical' molecules from marketing claims about compounded products.
boundary
Public communication is not primary trial evidence. The cited TED biography supports the role described here; a current Kaiser affiliation was not established.
reviewed at
2026-10-01
name
Monica Christmas
credential
MD; University of Chicago obstetrician-gynecologist, director of its menopause program and Center for Women's Integrated Health
official url
https://www.uchicagomedicine.org/find-a-physician/physician/monica-christmas
public usefulness
Official physician profile and public Q&A explain how symptom care differs across patients.
contribution
Patient-centered menopause education supports reviewing purpose, benefit and risks over time.
boundary
Her inclusion does not imply endorsement of this article or establish one treatment duration for all readers.
reviewed at
2026-10-01
name
Nancy E. Avis
credential
PhD; SWAN investigator and lead author of the vasomotor-duration analysis
official url
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2110996
public usefulness
The primary report's accessible duration findings replace the common one- or two-year expectation.
contribution
SWAN longitudinal analysis of frequent vasomotor symptoms reports median duration and variation by timing and group.
boundary
Primary-paper role verified; current faculty appointment is not claimed. Cohort medians do not predict one person's course.
reviewed at
2026-10-01
name
Susan M. McCurry
credential
PhD; Research Professor Emeritus, University of Washington School of Nursing
official url
https://nursing.uw.edu/person/4376497-susan-m-mccurry/
public usefulness
Official profile describes clinical psychology and sleep research in older adults and people with coexisting conditions, including menopause.
contribution
Led the MsFLASH telephone-CBT-I trial showing sustained insomnia improvement without lower between-group flash frequency.
boundary
Selected clinical trial does not establish equivalence of an app, unsupervised sleep restriction or apnea treatment.
reviewed at
2026-10-01

Download original public profile Download complete article

End of Menopause and the years around it